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THE ROLE OF CXCR2 IN PANCREATIC CANCER DEVELOPMENT AND 
PROGRESSION 
Abhilasha Purohit Ph.D. 
University of Nebraska Medical Center, 2015 
Supervisor: Rakesh K. Singh, Ph.D. 
This dissertation examines the role of CXCR2, a seven transmembrane G- 
protein coupled receptor, in mediating autocrine as well as paracrine 
mechanisms during pancreatic cancer progression. Data presented in the initial 
section demonstrates the aberrant expression of the CXCR2 biological axis in 
human pancreatic cancer tissue specimens. A study performed within the first 
section of this dissertation investigates the contribution of CXCR2 signaling in 
pancreatic cancer initiation. These studies have identified a novel role of CXCR2 
in mediating KRAS(G12D) -induced  autocrine growth transformation of pancreatic 
cancer cells. The upregulation of the CXCR2 biological axis was found to be 
directly regulated by the KRAS(G12D) mutation using in vitro and in vivo model 
systems. Furthermore, the inhibition of CXCR2 by genetic and pharmacological 
tools was able to downregulate the protein level of KRAS.  
The tumor microenvironment in pancreatic cancer is composed of 
heterogeneous populations of cells including endothelial, fibroblast and immune 
cells. CXCR2 is known to be expressed by a majority of these cell types. 
Besides, CXCR2 is also known to mediate immune responses in various 
diseases including cancer. The studies in the later section of this dissertation 
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investigate the role of CXCR2 in altering local and systemic host-mediated 
responses in pancreatic cancer. Two experimental strategies were used: 1) 
Evaluating the impact of host CXCR2 depletion on tumor growth in subcutaneous 
versus orthotopic tumor cell implants. 2) Examining the effect of host CXCR2 
deletion on the infiltration of immune cells in orthotopic pancreatic tumors. The 
first approach identified a pancreatic-parenchyma specific role of CXCR2 in 
inhibiting fibrosis in pancreatic cancer. The second strategy unraveled an 
important role of CXCR2 in causing local immunosuppression where CXCR2 
mediates the infiltration of myeloid-derived suppressor cells (MDSCs) in 
pancreatic cancer. However, CXCR2 was found to be important for inhibiting 
extramedullary hematopoiesis and expansion of MDSCs in the spleen. Overall, 
the results presented in this dissertation suggest that CXCR2 signaling functions 
as a double-edged sword in pancreatic cancer by mediating both tumor-
promoting and -inhibitory effects.  
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Significance of the study: 
 Pancreatic cancer (PC) remains a challenging disease due to its 
aggressive tumor growth, early metastatic dissemination and late clinical 
presentation. Due to these factors, the prognosis of PC is extremely poor, 
leading to 100% mortality. In the pursuit to improve the clinical outcome of this 
disease, research focusing on the discovery of early detection markers is 
warranted. Extensive research efforts have led to significant insights into the 
genetic alterations occurring in PC. By understanding the molecular mechanisms 
linked with the early genetic events and further unraveling their phenotypic 
implementation, identification of novel diagnostic and therapeutic markers for the 
disease can be achieved.  Several studies have established the importance of 
inflammatory cells and mediators in PC inception and progression. However, the 
molecules regulating the inflammatory responses in PC remain largely unknown. 
Here we present a research effort to identify therapeutically targetable 
inflammatory mediators regulating various autocrine and paracrine effects during 
the inception and progression of PC.  The results generated in this study may aid 
in the development of novel therapeutic modalities for PC in the future.     
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Overview of the Anatomy and Histology of the Normal Pancreas: 
Anatomy:  
The pancreas is a 6 cm long, fish-shaped gland located in the abdomen 
and is anatomically divided into a head, body and tail. The head is the expanded 
portion that lies in the C-shaped curve of the duodenum, attached to the same by 
connective tissue. The centrally located body of the pancreas crosses the midline 
of the human body, and the tail extends towards the hilum of the spleen. The 
pancreatic duct (of Wirsung) extends through the length of the pancreas and 
empties into the duodenum at the hepatopancreatic ampulla (of Vater), through 
which the common bile duct from the liver and gallbladder also enters the 
duodenum. The hepatopancreatic sphincter (of Oddi) surrounds the ampulla and 
not only regulates the flow of bile and pancreatic juice into the duodenum but 
also prevents the reflux of intestinal contents into the pancreatic duct. In some 
individuals, an accessory pancreatic duct (of Santorini) is present as a vestige of 
pancreatic origin. A thin layer of moderately dense connective tissue forms the 
capsule around the glands. From this capsule, septa extend into the gland 
dividing it into ill-defined lobules. 
 Histology:  
Microscopically the pancreatic tissue can be divided into two parts: the 
exocrine components (acinar glands and ducts) that produce and deliver 
digestive enzymes to the small intestine and the endocrine components (Islets of 
Langerhans) that secrete hormones (including insulin) into the blood stream. The 
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histology of these two parts is evidently discrete and can be seen as lightly 
stained and darkly stained tissue. The light stained Islets of Langerhans are 
comprised of alpha cells secreting glucagon, beta cells secreting insulin and 
delta cells that secrete somatostatin. Additionally, this tissue also includes PP 
cells that secrete pancreatic polypeptide. For the effective functioning as an 
endocrine tissue, this compartment of the pancreas is sufficiently vascularized, 
such that this tissue lies in close vicinity of blood vessels. 
Pancreatic cancer: 
 PC is less frequent in occurrence compared with several other cancers 
including those of lungs, breast, stomach, liver, large bowel and prostate. 
However, the disease has a mortality rate in comparison to other cancer types 
(Lowenfels and Maisonneuve, 2006).  The American Cancer Society estimates a 
total of 48,960 new cases and 40,560 deaths for both sexes in the year 2015. 
The incidence of PC is more prevalent in males than females. For the year 2015, 
estimated new cases for males and females are 24,840 and 24,120 respectively. 
The estimated death numbers for each sex are 24,120 for males and 19,850 for 
females. Overall PC is ranked as the fourth leading cause of cancer-related 
deaths for the year 2015. The combined five-year survival rate of all other cancer 
types has shown tremendous improvement in the last few decades. In 1977, the 
combined five-year survival rate of all cancer types was 49%, which improved to 
68% in the year 2010. However, for the cancers of the pancreas this 
improvement rate is fairly small. In 1977, the five-year survival rate for PC was 
3%, which improved to only 7% in the year 2010. One of the explanations for the 
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poor survival of PC patients is provided by the fact that 53% of patients (all 
races) have distant metastasis at the time of diagnosis (Siegel et al., 2015). 
Therefore, one of the major challenges in the field of PC is early detection at a 
stage where cancer has not metastasized and surgical resection is possible.   
Risk factors for pancreatic cancer development:  
Based on descriptive epidemiology: 
Gender:  Cancer of the pancreas is more common in males than in females. The 
life-time cumulative risk for development of PC is higher in males than in females 
(Lowenfels and Maisonneuve, 2006; Raimondi et al., 2009).  
Geographical variations: The rate of PC is higher in northern countries like 
Iceland, Finland and the northern USA than the countries located closer to the 
equator such as Egypt, Zimbabwe and India (Raimondi et al., 2009). One of the 
proposed reasons for this variance is decreasing levels of Vitamin D due to less 
exposure to sunlight and UV rays in the populations located in the north 
(Raimondi et al., 2009). 
Age: PC is a cancer of elderly people. The median age of diagnosis of PC is 72 
years and only about 5-10% of patients develop PC before the age of 50 
(Raimondi et al., 2009). The American Cancer Society reports the comparatively 
highest number of deaths 10,594 (males) and 9,076 (females) in the age group 
60-79 years compared with other ages (Siegel et al., 2015). 
 
6 
 
Based on environmental factors: 
Smoking: Exposure to tobacco smoke is known to cause about 25% of PC cases 
(Kamohara et al., 2007). 
Dietary factors: Caloric consumption has been linked to the risk of PC (Lowenfels 
and Maisonneuve, 2006). Coffee and alcohol are not associated with the risk of 
PC. Vitamin D supplementation in the diet is known to have a protective role in 
PC (Raimondi et al., 2009).  
Genetic risk factors: Germline mutations account for 5-10% cases of PC. 
Increased rate of PC is linked with various familial syndromes such as Peutz-
Jeghers syndrome, familial atypical mole-multiple melanoma, cystic fibrosis and 
Li-Fraumeni syndrome (Raimondi et al., 2009). 
Disease based: Preexisting diseases like diabetes, pancreatitis and obesity are 
linked with increased risk of PC (Lowenfels and Maisonneuve, 2006; Raimondi et 
al., 2009). An increased risk of PC, up to 50%, was reported in patients with type 
2 diabetes for more than 10 years. An increased risk of PC (14 fold) was found in 
patients with chronic pancreatitis for at least 5 years (Raimondi et al., 2009).  
Causative mutations of pancreatic cancer: 
 The signature genetic events of the evolving pancreatic ductal 
adenocarcinoma (PDAC) lesions include mutations of KRAS, CDKN2A, TP53, 
BRCA2 and SMAD4/DPC. As the precancerous lesions, pancreatic intraepithelial 
neoplasia (PanINs), progress to higher grades the number of genetic alterations 
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increase paralleled with atypical growth stages. Activating mutations in the KRAS 
oncogene are the first genetic events to be detected. Loss of heterozygosity at 
chromosome 9q, 17p and 18q are known to contribute to the mutations of 
CDKN2A, TP53 and SMAD4 respectively. As the focus of this thesis is to 
elucidate the early mechanisms of PC development, we will only discuss the 
details of KRAS mutations.  
 Activating mutations in KRAS are the earliest genetic events found in 
nearly 95% of PDAC cases. KRAS belongs to the family of small 21-30kDa 
GTPase, having the potential to cycle between a GTP-bound on-state and GDP-
bound off-state. However, the event of a point mutation in this protein results in 
constitutive activation of RAS leading to persistent downstream signaling. The 
exclusively mutated form of RAS protein found in PC is KRAS and the 
predominant version occurs at position G12. Pharmacological approaches to 
block mutant KRAS have not transitioned into effective anti-KRAS therapies in 
clinics. Therefore, research focusing on targetable downstream effectors of RAS 
is necessary.    
Histological classification of pancreatic cancer: 
 The histology of pancreatic tumors forms the foundation of not only the 
understanding these tumors but also their prognosis. The prognostic value of PC 
histology is reflected in the fact that the majority of cancers of the pancreas with 
a fatal prognosis are adenocarcinomas of the exocrine pancreas. The survival 
time among PC cases varies by histologic type; specifically patients diagnosed 
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with endocrine PC survive almost 2 years longer than those diagnosed with 
exocrine PC (Fesinmeyer et al., 2005). The apparent higher fatality of exocrine 
tumors is inexplicable, but may be attributed to their cellular or molecular 
behavior. For example, PDAC generally blocks the pancreatic duct, resulting in 
jaundice and cachexia. In contrast, endocrine pancreatic tumors often 
overproduce normally occurring substances such as insulin and glucagon. In this 
section, we will briefly review the histological classification of PC. 
Tumors of the exocrine pancreas: The World Health Organization and 
International Agency for Research on Cancer has extensively classified tumors 
that affect the exocrine portion of the pancreas. The tumors of the exocrine 
pancreas are sub-classified into PDAC (75% cases), serous cystadenoma, 
mucinous cystadenocarcinoma, intraductal papillary-mucinous carcinoma and 
acinar cell carcinoma. PDAC is further subdivided into well differentiated or 
poorly differentiated types, and are the most frequent exocrine tumors with the 
poorest prognosis. Contrary to these, the next three are rare tumors. Finally, the 
group of rarest exocrine tumors arises from acinar cells. Additionally, 
pancreatoblastoma is a rare form of PC that affects children. For the purpose of 
this dissertation we will focus on the histology of the most malignant of all 
pancreatic epithelial tumors, PDAC. 
(i) Pancreatic ductal adenocarcinoma: PDACs arise from and are 
phenotypically similar to pancreatic duct epithelia and constitute about 85-90% of 
all pancreatic neoplasms. Most ductal adenocarcinomas are moderately or well-
differentiated tumors consisting of tubular or glandular structures formed by 
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mucous secreting columnar cells. The majority of ductal adenocarcinomas show 
KRAS mutations (Hruban et al., 2004).  
Macroscopic view: Ductal adenocarcinomas are firm and poorly defined 
masses. PDACs are highly invasive cancers and have a tendency to invade the 
nearby tissues. Around 65% of PDACs arise in the head, 15% arise in the body 
and 10% in the tail. Based on the anatomy, the carcinomas of the head of the 
pancreas invade the common bile duct or the main pancreatic duct and produce 
stenosis.  Advanced cases involve the ampulla of Vater or the duodenal wall. In 
contrast to these, the carcinomas in the pancreatic body and tail obstruct the 
main pancreatic duct only (Kloppel and Hruban et. al., WHO). 
Histopathology of PDAC:  
The hallmark feature of PDAC is the presence of a dense stromal 
response referred to as desmoplasia. Most ductal adenocarcinomas imitate 
normal pancreatic ducts embedded inside a thick stroma. The desmoplastic 
stroma in PDAC is known to be composed of fibroblasts, stellate cells, 
endothelial and immune cells. The large amount of fibrous stroma accounts for 
their firm consistency. To appreciate the histopathology of PDAC an 
understanding of the histological features is a must. The following is a summary 
of the key histological features of infiltrating ductal adenocarcinoma.  
i) The presence of glandular tissue at places where it should not be 
found. Unlike the non-neoplastic tissue that consists of lobular units 
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with ducts at the center surrounded by acini, the growth pattern in 
PDAC is haphazard and the glands violate the lobular architecture.  
ii) The presence of glands adjacent to muscular arteries without 
intervening pancreatic parenchyma.  
iii) Perineural and intravascular invasion. 
iv) The presence of nuclear polymorphism and the finding of nuclei in a 
single gland varying in area by more than 4 to 1.  
v) Detection of necrotic debris within the lumen. 
PanIN lesions:  
 Histological evaluation of areas surrounding PCs have revealed the 
presence of precursor lesions known as PanINs. PanINs are microscopic 
neoplastic proliferations in the pancreatic ducts and are subdivided into grades 
PanIN-1 to -3. Progression from PanIN-1 to -3 stage is accompanied by the 
onset of various mutations and increasing cellular and nuclear atypia. Discovery 
of these precursor lesions has provided a ray of hope that PC might be detected 
and cured in its preinvasive stages (Hruban et al., 2000; Hruban et al., 2008). 
Tumors of the endocrine pancreas: 
 Tumors of the endocrine pancreas are relatively uncommon. They arise 
from the endocrine parts of the pancreas, the islets of Langerhans, and are sub- 
classified into insulinoma, glucagonoma, somatostatinoma and nonfunctional 
islet cell tumors (Gumbs et al., 2002). 
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CXCR2 and its ligands and introduction: 
The members of the supergene family of chemotactic cytokines i.e. 
chemokines, are inflammatory mediators that recruit leukocytes to an area of 
evolving inflammation (Baggiolini, 1998; Epstein and Luster, 1998). They are 
small secreted proteins, 60-90 amino acids in length and 8-10 kilodaltons in 
mass. Chemokines were mainly discovered based on either the biological activity 
instigated by them or their ability to be expressed based on specific stimulation 
(Baggiolini et al., 1994b). Platelet factor 4 (PF4) was the first discovered 
chemokine reported in 1977 (Walz et al., 1977). Historically, chemokines were 
classified into sub-families based on the patterns of their N-terminal cysteine 
residues (Zlotnik and Yoshie, 2000). Currently, there are four main sub-families 
of chemokines known: CXC, CC, CX3C and C (Zlotnik and Yoshie, 2000). Apart 
from their structures, the members of the different families of chemokines differ in 
their target cell selectivity (Baggiolini et al., 1994b) and the chromosomal location 
of their genes (Baggiolini et al., 1994a). Subsequent research efforts after the 
initial discovery of chemokines have highlighted their functions as and even 
beyond the initially identified role of immune cell recruiters (Slettenaar and 
Wilson, 2006). The CXC family of chemokines is comprised of 17 members, 
which are further classified into two groups based on the presence or absence of 
a three amino acid motif glutamic acid-leucine-arginine (ELR). Seven CXC 
chemokine receptors have been identified to date (CXCR1-7) (Lazennec and 
Richmond, 2010).  
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ELR motif-positive CXC chemokines: 
Preceded by the discovery of PF4, CXCL8 was the first identified CXC 
chemokine (Baggiolini et al., 1994a). In 1987 Walz et al., isolated CXCL8 from 
the conditioned media of LPS-stimulated human blood mononuclear cells (Walz 
et al., 1987b). Further studies identified CXCL8 as a chemotactic factor and 
activator of neutrophils (Van Damme et al., 1988). Following the discovery of IL8 
other CXC chemokines were discovered in rapid succession. CXCL7 (NAP-2) 
was identified in the conditioned media of monocytes cultured in the presence of 
blood platelets (Baggiolini et al., 1994a; Walz and Baggiolini, 1989). CXCL1 
(GROα) was identified as a melanoma growth stimulator (MGSA) (Richmond and 
Thomas, 1988). Later GROβ (CXCL2) and GROγ (CXCL3) were also discovered 
(Haskill et al., 1990). CXCL5 was identified as a product of type II alveolar cells 
(Walz et al., 1991) and CXCL6 was isolated from the conditioned media of 
human osteosarcoma cells (Proost et al., 1993). Functionally, all these 
chemokines demonstrated the ability to attract and activate human neutrophils. 
CXCL8 shares 33 to 46% sequence identity with other ELR+ CXC chemokines 
(Baggiolini et al., 1994a). The N-terminal ELR motif preceding the first cysteine is 
necessary for the chemotactic activity towards neutrophils. The genes for these 
chemokines are co-localized on human chromosome 4q12-21(Raimondi et al., 
2009). The activity of these CXC chemokines is mediated through two CXC 
receptors, CXCR1 and CXCR2 (Richmond and Thomas, 1988).                               
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CXCR2: A synopsis: 
 CXCR2 is a seven-transmembrane G-protein coupled receptor having 
three extracellular and three intracellular loops (Hertzer et al., 2013). The 
extracellular N-terminal domain is necessary for ligand binding and the 
intracellular C-terminal domain is required for receptor internalization (Hertzer et 
al., 2013). Biochemically, CXCR2 is a 360 amino acid glycoprotein (Chapman et 
al., 2009). CXCR2 is known to have 78% amino acid homology with CXCR1 
(Holmes et al., 1991). CXCR2 is known to bind with all the ELR+ ligands; 
however, CXCR1 binds only CXCL6 and 8 (Lazennec and Richmond, 2010). 
Expression of CXCR2 has been detected in several cell types including epithelial 
cells, endothelial cells, fibroblasts, neuronal cells and immune cells like 
neutrophils, monocytes and  mast cells (Raimondi et al., 2009).  The normal 
physiological functions of CXCR2 include regulation of neutrophil homeostasis  
(Devalaraja et al., 2000; Slettenaar and Wilson, 2006). CXCR2 is also known to 
play key roles in wound-healing mechanisms (Devalaraja et al., 2000). CXCR2 is 
suggested to be a negative regulator of myeloid progenitor cell proliferation and 
their migration as CXCR2 knock-out (Cxcr2-/-) mice show hyperproliferation of 
myeloid progenitor cells in the bone marrow, spleen and blood (Rollins, 1999). 
 Pathologically the CXCR2 biological axis is implicated in several autocrine 
and paracrine tumor-promoting roles in various cancers including melanoma 
(Singh et al., 2009; Varney et al., 2006), breast  (Kitamura and Pollard, 2015; 
Sharma et al., 2015), colorectal  (Desurmont et al., 2015; Wu et al., 2015) and 
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lung (Keane et al., 2004). As the focus of research presented in this dissertation 
is PC, we will provide a summary of existing information regarding CXCR2 in PC. 
                                        CXCR2 in Pancreatic cancer 
Introduction:  
In this section, we will give an overview of the current knowledge and the 
persisting gaps in understanding the role of CXCR2 and its ligands in PC. We will 
first provide information regarding the expression of CXCR2 and its ligands in 
human PC patient samples and cell lines. Later we will review the role of the 
CXCR2 biological axis in mediating tumor-associated phenotypes in PC. Lastly, 
we will summarize the oncogenes and signaling pathways stimulating the 
induction of CXCR2 and its ligands in PC. 
CXCR2 in pancreatic cancer cell lines:  
  The expression of CXCR2 in human PC cell lines is still a matter of 
debate. In recent years, a number of research groups have identified expression 
of CXCR2 in PC cell lines (Le et al., 2000; Wang et al., 2013b). On the other 
hand, researchers have also reported that PC cell lines lack the expression of 
CXCR2 (Matsuo et al., 2009e). For instance, cell lines like Panc-1, MIA Paca-2, 
and Capan-2 have been reported as both positive and negative for CXCR2 
expression by different research groups. 
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Expression of CXCR2 and its ligands in pancreatic cancer human samples:  
Tissue Specimens:  
CXCL1: Evaluation of protein lysates derived from human PC tissues 
demonstrated detectable levels of CXCL1 protein and showed a non-significant 
increase in relation to adjacent tumor-free neighboring tissue (Oliveira Frick et 
al., 2008). 
CXCL5: Recent research reports have provided extensive evidence for the 
expression and pathological role of CXCL5 in PC using human tissue specimens. 
Significantly increased levels of CXCL5 were detected in the tumor tissue lysates 
of PC by ELISA compared with the surrounding normal tissue or other 
histopathologically distinct diseases of the pancreas including chronic 
pancreatitis. Furthermore, in the same study the authors confirmed the cellular 
location of CXCL5 in PC tissues by IHC. The expression of CXCL5 was 
extensively localized in the cytoplasm of the malignant ductal cells while the 
surrounding normal tissues demonstrated no substantial expression of the ligand 
except in some acinar cells and islets of Langerhans (Oliveira Frick et al., 2008). 
In a recent study Li et al., also identified the expression of CXCL5 in human 
tissue specimens and further established its correlation with disease progression 
and survival. They found that CXCL5 expression was occasionally present in 
PanIN-1 lesions but increased in  PanIN-2 and PanIN-3 stages where 4 out of 
the total 11 specimens demonstrated high immunoreactivity for CXCL5 (Li et al., 
2011c). Moreover, strong staining for CXCL5 was detected in 67% of PC 
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specimens. CXCL5 staining was found to be localized to the apical cytoplasm in 
the tumor cells while there was no immunoreactivity in the acinar and ductal 
epithelium of the normal pancreas. Based on these results, the authors 
concluded that the expression of CXCL5 correlates with tumor progression in PC. 
Furthermore, by performing Kaplan-Meier analysis they established that high 
CXCL5 expression shortened patient survival time. The authors also reported 
higher microvessel density in tumors with higher expression of CXCL5 
suggesting its role in neoangiogenesis (Li et al., 2011c).     
CXCL6:  PC tumor lysates were shown to have detectable levels of CXCL6; 
however, there was no significant difference in its expression in tumors versus 
the surrounding normal tissue (Oliveira Frick et al., 2008).  
CXCL7: CXCL7 protein demonstrated no differential in expression between the 
PC and the adjacent normal tissue (Oliveira Frick et al., 2008).  
CXCL8: Compared with other members of its family, CXCL8 is the most 
extensively studied ligand for its pathological significance in human tissue 
specimens of PC. Xiangdong et al. for the first time, reported the higher 
expression of CXCL8 protein in human PC tissue specimens (n=45) compared 
with the normal pancreas (n=15). Its expression was localized to the ductal cells 
as well as the stroma (Le et al., 2000). Later, Kuwada et al. supported these 
observations by reporting the expression of CXCL8 in 20 out of 50 patient tissue 
specimens evaluated. CXCL8 was found primarily in the cytoplasm of the tumor 
cells (Kuwada et al., 2003). In further support of these observations, another 
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study identified higher expression of CXCL8 protein in PC tumor lysates 
compared to non-affected neighboring tissue. IHC analysis revealed that CXCL8 
was located in the cytoplasm of the ductal epithelial cells as well as the infiltrating 
inflammatory cells. The authors evaluated the expression of CXCL8 in different 
tumor stages based on TMN classification of malignant tumors. Expression of 
CXCL8 was upregulated in the T3 and T4 versus the T1 and T2 stages (Oliveira 
Frick et al., 2008). In contrast to this report that did not detect CXCL8 in the 
normal pancreas a recent study detected expression of CXCL8 in both PC 
(55.6%) and non-cancer tissues (25.9%). They found positive signals localized in 
both normal and cancerous ducts (Chen et al., 2012).  
CXCR2: Little focus has been placed thus far on the evaluation of the 
pathological significance of CXCR2 expression using human PC tissue 
specimens. Positive immunoreactivity for CXCR2 was reported by Kuwada et al. 
in 26 out of 40 (65%) surgically resected human PC tissues (Kuwada et al., 
2003). However, the authors did not evaluate the expression of CXCR2 in normal 
tissue. In another study, Frick et al. reported that CXCR2 was expressed in PC 
tumor tissue and also in the corresponding non-affected tissue from the same 
patients (Oliveira Frick et al., 2008). A recent report by Hussain et al. evaluated 
the expression of CXCR2 along with CXCR1 and CXCL8 in PDAC and 
pancreatic neuroendocrine tumors by IHC (n = 52) and qRTPCR (n = 8). CXCR2 
expression was detected in PDAC samples at both the mRNA and protein levels.   
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CXCR1: 
 A recent report by Chen et al. identified the presence of CXCR1 in human 
PDAC specimens. 61% of cases (40 out of 65) were positive for CXCR1 
expression.  On average, around 14.7% cells were positive in each of these 
specimens.  The expression of CXCR1 significantly correlated with lymph node 
metastasis in these patients (Chen et al., 2014). However, there was no 
association found with other clinical prognostic features such as histopathological 
grade, depth of invasion or TMN stage.  They also identified a positive correlation 
of CXCR1 with cancer stem cell markers like CD44 and CD133 (Chen et al., 
2014).  
Serum samples and body fluids: 
 O’Hayer et al. evaluated the expression of ELR+ CXC chemokines 
hCXCL1, 5, 6, 7 and 8 in serum samples isolated from 20 PC patients and 19 
age- and sex- matched healthy donors. Their results demonstrated significantly 
elevated expression of CXCL1 and CXCL7 in PC specimens. No change in the 
expression of CXCL5, 6 and 8 was observed in PC serum samples compared 
with healthy donors (O'Hayer et al., 2009). Moreover, a recent study reported 
significantly higher levels of CXCL8 in serum samples of PC patients compared 
with specimens derived from patients of acute or chronic pancreatitis (Chen et 
al., 2012). Matsuo et al. evaluated the levels of ELR+ CXC chemokines (CXCL1, 
5 and 8) in the secretin-stimulated pancreatic exocrine secretions of PC patients 
and healthy individuals. Their data demonstrates significantly enhanced secretion 
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of CXCL5 or cumulative expression of ELR+ CXC in PC patients versus healthy 
individuals. However, they did not observe a significant  change in the individual 
expression of CXCL1 and CXCL8  (Matsuo et al., 2009e). 
CXCR2 ligands as autocrine growth factors in pancreatic cancer: 
Presently the role of CXCR2 ligands as growth factors for PDAC tumor 
cells is an area of contention. While numerous data is supporting the theory of 
CXCR2-mediated tumor cell autochthonous growth, several of the recent reports 
highlight also the notion that CXCR2 agonists fail to provoke the growth of PC 
cells.  Takamori et al. identified the expression of CXCR2 and its ligands, CXCL1 
and 8 in Capan-1 cells. They found that treatment with anti-CXCL8 or anti-
CXCL1 antibody inhibited the growth of Capan-1 cells (Takamori et al., 2000). In 
line with these observations, Kamohara et al. also demonstrated that neutralizing 
antibody for CXCL8 (1-100 µg/ ml) was sufficient to suppress significantly the 
autocrine growth of PC cell lines, including SUIT-2 and Capan-1 (Kamohara et 
al., 2007). Furthermore, while identifying the presence of a CXCR2 
macromolecular signaling complex in PDAC cells, a recent study provided 
another functional evidence for the role of CXCR2 signaling in mediating in vitro 
and in vivo tumor cell growth. Their data revealed that treatment of PDAC cell 
lines HPAC and Colo357 with CXCR2 agonists (including CXCL1, 5 and 8) 
enhanced in vitro cell proliferation. Similarly, disruption of the CXCR2 
macromolecular complex by using an exogenous CXCR2 C-tail sequence in 
HPAC cells significantly attenuated its in vitro and in vivo proliferation (Wang et 
al., 2013b).  
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 In contrast to the studies described above, several groups have 
provided evidence that PDAC cell lines either lack the expression of CXCR2 
(Matsuo et al., 2009d), or the receptor is unresponsive to its agonists (Ijichi et al., 
2011a; Matsuo et al., 2009a). To reconcile this discrepancy, further 
experimenting with an advanced model system is required. For example, 
conditional in vivo deletion of CXCR2 in the ductal cells of spontaneous PDAC 
murine models can overcome the limitations of in vitro and orthotopic in vivo 
models systems used thus far. 
Involvement of CXCR2 signaling in pancreatic cancer stroma: 
 In an in vitro co-culture system, CXCL8 produced by PC cells was shown 
to enhance angiogenesis in cooperation with CXCL12 produced by the 
fibroblasts (Matsuo et al., 2009d). More recently, Ijichi et al. reported the much 
higher expression of CXCR2 mRNA transcripts in pancreatic fibroblasts 
compared with PDAC cells isolated from Ptf1acre/+;LSL-KrasG12D/+ mice.  
Furthermore, the expression of Ctgf, a profibrotic factor, was found to be induced 
in pancreatic fibroblasts treated with PDAC-conditioned media and this induction 
was inhibited by incubating fibroblasts with PDAC-conditioned media containing 
CXCR2 antagonist. They also provided evidence for the role of CXCR2 signaling 
in accelerating PDAC progression by promoting tumor-stromal interaction. 
Subcutaneous implants of PDAC cells mixed with fibroblasts showed accelerated 
tumor growth compared with only PDAC cell implants. More importantly, CXCR2 
knock-down in fibroblasts inhibited the subcutaneous tumor growth while CXCR2 
knock-down in the tumor cells caused no effect. Based on these results, the 
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authors postulated that CXCR2 signaling indirectly supports PDAC progression 
by mediating tumor-stromal interaction and has no autocrine growth enhancing 
effect on tumor cells (Takamori et al., 2000).  
CXCR2 in mediating pancreatic cancer angiogenesis:  
The CXCR2 signaling axis has been well appreciated for its role in 
mediating angiogenesis in various cancers. Moritz et al. (2006) for the first time 
reported the angiogenic activity of CXCR2 signaling in PC by evaluating 
angiogenesis induced by culture supernatants of PC cell lines in vivo using the 
corneal micropocket assay. They demonstrated that CXCR2 antibody completely 
inhibited the in vivo angiogenic response stimulated by BxPC3 culture 
supernatants (Wente et al., 2006). In another study, Matsuo et al. identified  a 
similar mechanism in vitro by demonstrating that the higher CXCL8-producing 
PC cell line BxPC3 enhanced the invasiveness and tube-forming ability of human 
umbilical vein endothelial cells (HUVECs) and that treatment with CXCL8 
antibody abrogated this effect (Matsuo et al., 2009d). Another study by the same 
group demonstrated that CXCR2 antibody treatment significantly reduced 
microvessel density in an orthotopic nude mouse model (Matsuo et al., 2009e). 
Later they also established the role of CXCR2 axis in mediating KRAS-induced 
paracrine angiogenic effects in PC (Matsuo et al., 2009a). A recent study by 
Aihua Li et al. addressed the role of CXCR2 signaling in PC neovascularization 
with another view. Bone marrow-derived endothelial progenitor cells (EPCs) are 
known to differentiate into mature endothelial cells and form blood vessels. The 
authors found an increased presence of CD133+ and CD146+ cells in human PC 
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tissues compared with the normal pancreas. They also demonstrated increased 
subcutaneous tumor growth in mice implanted with a mixture of mouse PC cells 
with EPCs compared with the control group inoculated only with PC cells. Tumor- 
bearing Cxcr2-/- mice demonstrated a reduction in the levels of EPCs in bone 
marrow and blood. Congruent with this observation, the authors show that Cxcr2-
/- reduced the proliferation and capillary tube formation of bone marrow-derived 
cells in vitro (Li et al., 2011a).  
In vivo preclinical inhibition of CXCR2 in animal models: Approaches and 
outcomes: 
 Numerous studies provide data for the effect of CXCR2 inhibition on in 
vivo growth of PC cells. In a study aimed to identify the role of the CXCR2 
biological axis in PC, Matsuo et al. reported that treatment with CXCR2 antibody 
inhibited tumor growth and angiogenesis in an orthotopic nude mouse model 
having implantation of BxPC3 cells (Matsuo et al., 2009e).  Using a 
subcutaneous tumor model generated by inoculation of BxPC3 cells in nude mice 
Li et al. demonstrated that treatment with CXCR2 antiserum decreased tumor 
volume and microvessel density. Furthermore, in the same study the authors 
demonstrated that nude mice inoculated with MIAPaCa-2 cells subcutaneously 
showed reduced tumor growth in response to treatment with CXCL5 siRNA (Li et 
al., 2011c). Another study by the same group provided data that mouse PC cells 
harboring a KRAS mutation implanted in the pancreas of C57BL6 Cxcr2-/- mice 
developed significantly smaller tumors compared with the control wild-type group 
(Li et al., 2011b). Unlike the systemic inhibition of CXCR2 in previous models, a 
23 
 
recent study by Wang et al. employed the technique of disrupting the CXCR2 
macromolecular complex in tumor cells (HPAC) in vitro before subcutaneous 
implantation in CB17-SCID mice. They found that inhibition of CXCR2 in the 
tumor cells inhibited the tumor volume and in vivo tumor cell proliferation (Wang 
et al., 2013b). Treatment of Kras+TGFβr2-KO PDAC mice with the CXCR2 
antagonists repertaxin or SB225002, inhibited tumor size and angiogenesis (Ijichi 
et al., 2011a). However, contrary to the above results, the authors of a review 
focused on the potential of targeting CXCR2 signaling in PC revealed that mice 
heterozygous for CXCR2 injected with PC cells developed larger tumors than the 
wild type (WT group) (Hertzer et al., 2013).  
Oncogenes and CXCR2 signaling: 
 Upregulation of the ligands for CXCR2 is a well-known consequence of 
activating mutations in the KRAS oncogene.  For the first time, Sparmann et al. 
reported that activation of the RAS pathway leads to substantially increased 
CXCL8 production in Hela cells. Furthermore, based on their in vivo results they 
concluded that CXCL8 is required for RAS-oncogene-dependent tumor growth by 
mediating angiogenesis. In rapid succession, similar findings were reported for 
cancers of the lungs and ovaries. Matsuo et al. identified the link between 
KRAS(G12V) and KRAS(G12D) mutations and upregulation of cumulative expression 
of CXCL1, 5 and 8 in PC. Later, Hayer et al. reported that knock-down of 
endogenous KRAS(G12D) in the PC cell line SW1990 resulted in the reduction of 
transcripts of CXCL1, 2, 3, 5, 6, 7 and 8. Activation of MEK and cJun pathways 
are known to induce the expression of CXCR2 ligands downstream of KRAS 
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activation. However, the role of KRAS in inducing the expression of CXCR1 and 
2 remains less defined. 
Potential roles of the CXCR2 biological axis in pancreatic cancer immune 
microenvironment 
The previous section provides a summary of the currently known facts 
regarding the role of CXCR2 in PC. In summary, previous research efforts have 
addressed the potential involvement of CXCR2 in regulating the PC 
microenvironment by affecting the functions of fibroblasts and endothelial cells. 
However, the functional significance of CXCR2 in orchestrating the immune 
component within the PC tumor microenvironment (TME) remains unexplored. 
Therefore, in this section we focus on the well-identified roles of the CXCR2 
biological axis in the regulation of myeloid cell populations. Each subsection 
presents information linking CXCR2 and one immune cell type. Furthermore, we 
also summarize relevant reports related to each cell type in PC. Taken together, 
this information might help in understanding the potential roles played by the 
CXCR2 biological axis in the immune microenvironment of PC. 
Mast cells: 
 Mast cells are tissue resident cells of myeloid origin primarily known for 
their involvement in type I hypersensitivity reactions like allergy and anaphylaxis. 
However, mast cells also function to mediate the processes of wound healing 
and defense against pathogens. They are recruited to the target tissue as 
immature precursors where they remain sentinel and undergo terminal 
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differentiation in response to an external challenge (Collington et al., 2011; 
Maltby et al., 2009). Characteristically, mast cells degranulate upon stimulation 
and release an arsenal of effector molecules including histamine, heparin, 
tryptase and various cytokines (Gabrilovich and Nagaraj, 2009). Reports have 
recognized the presence of mast cell infiltrates in several cancer types including 
pancreatic tumors. Mast cells foster tumor growth primarily by mediating 
angiogenesis, remodeling the extracellular matrix to facilitate metastasis and 
suppressing anti-tumor immune responses (Khazaie et al., 2011; Maltby et al., 
2009). In PDAC, mast cells can be detected at the infiltrating edges of tumors. 
Also, mast cells are detected in precursor PanIN lesions suggesting their role in 
the early stages of this disease. Detailed information regarding the role of mast 
cells in PC is reviewed elsewhere (Evans and Costello, 2012; Wörmann et al., 
2014).  
 Mast cells are known to express both CXCR2 and its ligands. HMC1 cells, 
a human mast cell line, express CXCR2 and demonstrate concentration- 
dependent chemotaxis and F-actin polymerization in response to stimulation with 
Cxcl2, 5, 7 and 8 suggesting a role for CXCR2 in mast cell trafficking (Lippert et 
al., 1998; Nilsson et al., 1999). In a recent report Jenny et al. revealed an indirect 
role for CXCR2 in mast cell recruitment beyond the induction of directed cell 
migration. Using a model of inflamed lung they demonstrated that the absence of 
CXCR2 signaling in lung endothelium impairs the expression of VCAM-1, a 
critical counter ligand for α4 integrins expressed on mast cell progenitors, leading 
to decreased recruitment of mast cells (Hallgren et al., 2007).  
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 Evidence suggests that CXC chemokines can regulate mast cell-mediated 
regulation of other immune cells and thus exert effects beyond their chemotactic 
cell migration. CXCL1 and 2 released by mast cells are important for neutrophil 
recruitment in vivo. Furthermore, Wang et al. demonstrated that CXCL2-induced 
neutrophil recruitment was found to be mediated by TNF-α released from local 
mast cells (Wang and Thorlacius, 2005). Also, mast cell-derived CXCL2 was 
found to mediate the recruitment of neutrophils in T cell-mediated heparin-
induced delayed-type hypersensitivity reactions of skin (Biedermann et al., 2000).  
Lee et al. demonstrated that IL-1β evokes mast cells to produce CXCL8, 
which in turn induces angiogenesis (Lee et al., 2011). Interestingly, various 
studies on disease pathogenesis including psoriasis and rheumatoid arthritis 
identified mast cells as the predominant source of IL-17, which is a potent 
inducer of CXCR2 ligands (Lin et al., 2011). Thus, these IL-17-induced ligands 
can further cause infiltration of neutrophils or enhance the angiogenic response. 
Direct evidence for the role of CXCR2 signaling in the cross-talk between tumor 
and mast cells was demonstrated in a study using a thyroid cancer model. Mast 
cells were shown to enhance the in vitro survival and invasive ability of thyroid 
cancer cells via the secretion of CXCL1 (Melillo et al., 2010). Furthermore, 
conditioned media from thyroid cancer cell lines upregulated the secretion of 
CXCL1 from mast cells (Melillo et al., 2010). 
 The earliest study identifying the expression of CXCR2 in mast 
cells reported  higher expression of this receptor in the intracellular compartment, 
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suggesting its presence on the granules (Lippert et al., 1998). Therefore, there is 
a possibility that CXCR2 might be involved in the degranulation of mast cells. 
Taken together, these reports suggest a role for CXCR2 signaling in mast 
cell recruitment and also in mediating their cross-talk with stromal and tumor 
cells. Thus, based on this evidence it would be interesting to evaluate the role of 
this signaling axis in regulating mast cell pathology in various cancer types 
including PC.  
Myeloid-derived suppressor cells: 
 Myeloid-derived suppressor cells (MDSCs) are a phenotypically 
heterogeneous population of immature myeloid cells having only one common 
feature i.e. their ability to induce immunosuppression by causing defective T cell 
function (Fujimura et al., 2010). Canonically, they are divided into granulocytic 
(mouse: CD11b+Ly6G+; human: CD11b+ CD15+) and monocytic (mouse: 
CD11b+Ly6C+; human: CD11b+ CD14+) sub-populations (Goedegebuure et al., 
2011; Ostrand-Rosenberg and Sinha, 2009). In cancer, tumor-released factors 
stimulate myelopoiesis but block the differentiation of immature myeloid cells 
(IMCs) to mature myeloid cells like macrophages, dendritic cells and 
granulocytes. This IMC population is further activated by another group of factors 
resulting in the generation of immunosuppressive cells (with increased levels of 
ROS, arginase, and/or NO) collectively known as MDSCs (Gabrilovich and 
Nagaraj, 2009).   
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Patients with cancer are known to have a marked systemic expansion of 
MDSCs in spleen and lymph nodes and also in the number of circulating MDSCs 
in the blood (Gabrilovich and Nagaraj, 2009).  These MDSCs then get recruited 
to the tumors. Of note, MDSCs can cause immunosuppression at the tumor site 
as well as when located systemically. However, the mechanism of 
immunosuppression caused by MDSCs can be either antigen-specific or -
nonspecific depending on their location (Nagaraj and Gabrilovich, 2008). At the 
tumor site the immunosuppressive activity of MDSCs is mainly antigen-
nonspecific mediated primarily by the production of inducible nitric oxide 
synthase (iNOS) and arginase 1. iNOS and arginase 1 produced by MDSCs are 
known to suppress the proliferation and activation of T cells by inhibiting the 
expression of  MHC class II on antigen-presenting cells and CD3-ζ chains on T 
cells respectively (Fujimura et al., 2010; Gabrilovich and Nagaraj, 2009; 
Goedegebuure et al., 2011; Nagaraj and Gabrilovich, 2008). However, in the 
peripheral tissues MDSCs function as antigen-presenting cells and induce 
reactive oxygen species (ROS)-mediated T cell suppression during the antigen- 
specific interaction between MDSCs and T cells (Nagaraj and Gabrilovich, 2008). 
MDSCs are also known to cause indirect immunosuppression by promoting the 
recruitment of Tregs to the tumor sites and by blocking the entry of effector T 
cells (Goedegebuure et al., 2011).  
Several studies in cancer and other diseases have elaborated the role of 
CXCR2 signaling axis in MDSC trafficking. Chemotherapy in breast cancer 
induced TNF-α in the stromal compartment of tumors, which further upregulated 
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CXCL1 and 2 in the tumor cells both in tumors and the lung microenvironment. 
These upregulated chemokines in turn recruited CXCR2+ MDSCs, which 
enhanced the viability of cancer cells through S100 A8/9 factors (Acharyya et al., 
2012). MDSCs isolated from tumors of mice inoculated with B16-F10 melanoma 
demonstrated higher levels of CXC chemokines compared with bone marrow 
MDSCs from the same mice suggesting the role of these chemokines in 
trafficking of MDSCs to the tumors  (Wang et al., 2015). A report from Weiss et 
al. demonstrated that IL-2/αCD40 treatment caused a reduction in tumor-
associated MDSCs, which was accompanied by reduced CXCL5 protein 
expression in tumor lysates (Weiss et al., 2009). Furthermore, Toh et al. also 
demonstrated the role of CXCL1, 2 and 5 in the recruitment of granulocytic 
MDSCs to the primary tumors (Toh et al., 2011). Likewise, in a colitis-associated 
colon cancer model the levels of CXCR2 ligands were found to be elevated in 
inflamed mucosa and the loss of CXCR2 diminished the infiltration of 
granulocytic MDSCs from the circulatory system to colonic inflamed mucosa 
(Katoh et al., 2013). A recent report by Highfill et al. also demonstrated that 
CXCR2 deficiency inhibited the trafficking of granulocytic MDSCs to the tumors 
resulting in compensatory accumulation in the spleen and peripheral blood. They 
further concluded that CXCR2+ granulocytic MDSCs mediate local 
immunosuppression in murine rhabdomyosarcoma and that inhibiting CXCR2 
signaling can enhance the efficacy of checkpoint inhibitors (Highfill et al., 2014). 
 The presence of MDSCs has been recognized in both human specimens 
and mouse models of PC. In human PDAC specimens MDSCs were found to be 
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present in the tumor stroma and systemically in the peripheral blood, bone 
marrow and spleen (Porembka et al., 2012). Furthermore, Clark et al. (2007) 
identified the presence of MDSCs as early as the PanIN stage and found further 
increased infiltration in PDAC (Clark et al., 2007a). As several reports in PC 
suggest for enhanced CXCR2 signaling, further work is required to characterize 
the role of CXCR2 in MDSC trafficking in PC. 
Macrophages: 
 Tumor-associated macrophages (TAMs) are derived either from tissue 
resident macrophages or circulating blood monocytes. The primary recruiter of 
macrophages is monocyte chemotactic protein (MCP-1). The direct role of 
CXCR2 in inducing chemotaxis of monocytes for recruitment to tumors is not well 
defined. While CXCR2 is expressed by monocytes and macrophages (Moser et 
al., 1993; Murdoch et al., 2004; Patel et al., 2001), these cells do not respond to 
the stimulus provided by the CXCR2 ligands. The human monocytic cell line 
THP-1 demonstrated no chemotaxis in response to stimulation with different 
doses of rhCXCL8 (Bailey et al., 2007). Instead, there is evidence for indirect 
roles of CXCR2 signaling in the recruitment of macrophages. CXCL8 was shown 
to mediate the adhesion of rolling monocytes to endothelial cells expressing E-
selectin under flow conditions. However, these effects did not correlate with 
calcium induction or chemotaxis in monocytes (Gerszten et al., 1999). 
Interestingly, there is another mode of CXCR2-mediated monocyte recruitment 
via neutrophils.CXCR2-positive neutrophils recruited to tumors can secrete MCP-
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1, which in turn recruits monocytes from the blood. This indirect mechanism is 
discussed in detail in the coming paragraphs.  
Both the M1 and M2 activation stages of macrophages are linked with 
CXCR2 signaling. Treatment of monocytes with LPS and IFN-γ leads to the 
induction of the M1 phenotype and also of the ligands for CXCR2 like CXCL8 
(Gordon, 2003; Mantovani et al., 2004a; Mantovani et al., 2004b). However, the 
M1-activated macrophages are not known to express CXCR2 (Bonecchi et al., 
2000; Mantovani et al., 2004a). Thus, the ligands produced can exert paracrine 
effects by influencing CXCR2 positive elements of the TME. Although there is no 
direct evidence for the role of CXCR2 signaling in inducing M1- to M2-phenotypic 
switch, intracellular CXCR2 signaling is activated in M2 macrophages unlike M1 
counterparts (Melillo et al., 2010). IL-4 and IL-13 induce the M2a phenotype 
(alternatively activated) that demonstrate an inhibited CXCL8 production but 
make monocytes exquisitely sensitive to CXCR2 ligands by inducing the 
expression of the receptor CXCR2 (Mantovani et al., 2004b). Therefore, 
alternatively activated M2a macrophages have activated intracellular CXCR2 
signaling. On the other, hand M2c (deactivated) phenotype of macrophages has 
decreased expression of both CXCR2 and its ligands. Thus, in this receptor-
deprived state, macrophages are insensitive to exogenous CXCR2 ligands and 
also cannot affect the microenvironment by secreting ligands. Overall, while the 
evidence is indirect it is not unreasonable to conclude that based on the induction 
stimuli, the M1- to M2- macrophage switch might be mediated by CXCR2 
signaling.  
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CXCR2 signaling is a well-known facilitator in macrophage-neutrophil 
crosstalk. In 1989, CXCL8 was firstly identified in culture supernatants of 
stimulated human blood monocytes and it’s biological activity was demonstrated 
by its ability to attract and activate human neutrophils (Walz et al., 1987a).  More 
recently, Kaur and Singh (2013) identified CXCL8 as the major neutrophil 
chemoattractant produced by alveolar macrophages in chronic obstructive 
pulmonary disease, a condition characterized by neutrophilic airway inflammation 
(Kaur and Singh, 2013). Apart from neutrophils, CXCR2 signaling is also 
important for the crosstalk of macrophages with other cell types including 
endothelial cells. IL-1β-induced corneal neovascularization was found to be 
mediated by macrophages. Furthermore, the levels of the CXC chemokines KC 
(CXCL1), Mip-2 (CXCL2/3) and CXCL5 were found to be elevated in IL-1β 
implanted corneas. Depletion of macrophages by clodronate liposomes and the 
also treatment of these mice with an anti-mouse CXCR2 antibody inhibited IL-1β 
implanted corneal angiogenesis. These data provide indirect evidence that IL-1β 
induced CXC chemokines produced from macrophages enhance angiogenesis 
(Nakao et al., 2005). CXCR2 ligands secreted by macrophages can also 
generate interlinked networks between more than one cell types. For example, 
Zheng and Green reported the upregulation of CXCL8 in macrophages exposed 
to thrombin, an enzyme produced by leaky blood vessels. This thrombin-induced 
upregulation of CXCL8 was found to be regulated via PAR-1 by the Rho/Jnk 
pathway coupled to the activation of NF-κB and AP-1 transcription factors (Zheng 
and Martins-Green, 2007). Importantly, thrombin-induced expression of CXCL8 
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from the tissue-resident macrophages subsequently recruits neutrophils. These 
neutrophils in turn produce monocyte chemotactic protein (MCP-1) also known 
as CCL2, which further recruits monocytes (Gillitzer and Goebeler, 2001). Once 
recruited, monocytes differentiate into macrophages and produce CXCL8 that 
enhances angiogenesis and in turn maintains a paracrine crosstalk network in 
tumors. Thus, this evidence suggests that CXCR2 signaling is an important 
molecular mechanism involved in crosstalk between macrophages and cellular 
components of the tumor microenvironment including indirectly infiltrating 
monocytes.  
Dendritic cells: 
 Dendritic cells are antigen-presenting cells (APCs) capable of coordinating 
both innate and adaptive immune responses. They arise from hematopoietic 
stem cells in bone marrow as precursor cells and further differentiate into 
immature dendritic cells (iDCs). These iDCs are recruited to tumors where they 
encounter tumor-specific antigens and differentiate to mature dendritic cells 
(mDCs). The maturation of dendritic cells enables their migration to the next site 
of action, the secondary lymphoid organs, where they activate effector T cells 
leading to the generation of an adaptive anti-tumor immune response (Pinzon-
Charry et al., 2005). Tumor-derived factors are known to induce dysfunction of 
dendritic cells by affecting either their migration or maturation. Both anti- and pro-
tumor effects of dendritic cells have been reported in PC. High levels of 
circulating myeloid DCs were related to improved survival in PC (Hirooka et al., 
2011) and low levels of dendritic cell markers were negatively correlated with 
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survival rate (Tjomsland et al., 2011; Wörmann et al., 2014). On the contrary, a 
dendritic cell population was shown to accelerate pancreatic tumorigenesis by 
polarizing the T cell response to a protumorigenic Th-2 type (Ochi et al., 2012; 
Wörmann et al., 2014). 
 Evaluating the receptor expression and chemoattractant responsiveness 
of human dendritic cells isolated from peripheral blood monocytes, Sozzani et al. 
revealed the presence of detectable levels of CXCR2 and CXCR1 mRNA in 
dendritic cells. However, they concluded that dendritic cells do not respond 
biologically to CXCR2 signaling as the agonist CXCL8 failed to induce 
chemotaxis and calcium fluxes in dendritic cells in vitro (Sozzani et al., 1997; 
Sozzani et al., 1995). Parallel to these reports, other observers also reported the 
presence of  CXCL7 and 8 binding sites on dendritic cells but demonstrated a 
lack of migratory response induced by these chemokines (Xu et al., 1996). 
Contrary to these observations, a recent study presented results of CXCL8- 
induced chemotactic attraction of dendritic cells. The authors concluded that this 
discrepancy can be attributed to the dissimilarity in the conditions employed to 
differentiate dendritic cells in the two studies (GM-CSF and IL-13 vs. GM-CSF 
and IL-4) highlighting the relevance of the in vivo cytokine milieu in altering the 
functional contribution of CXCR2 signaling in dendritic cell biology in tumors 
(Feijoó et al., 2005). In the same report, the authors observed that intratumoral 
injections of dendritic cells transfected to produce IL-12 failed to migrate to 
secondary lymphoid organs. As they detected high expression of IL-8 in serum 
samples of human patients (including PC) and tissue culture supernatants of 
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various cancer cell lines, they suggested IL-8 was the candidate molecule 
mediating the retention of dendritic cells inside the tumors. They further 
supported their conclusion by in vitro classical chemotaxis assays where they 
found that chemotaxis of dendritic cells towards MIP-3β was diminished by 
culture supernatants of colon cancer cells and that this effect was overcome by 
treatment with a neutralizing anti-IL8 specific monoclonal antibody (Feijoó et al., 
2005). These data provide evidence for the potential role of CXCR2 signaling in 
causing tumor immunoevasion by impeding dendritic cell-activated anti-tumor T 
cell responses. CXCR2 is suggested to indirectly mediate circulating dendritic 
cell recruitment via adhesion to endothelial cell-displayed ligands like CXCL8 and 
CXCL1 (Cavanagh and Von Andrian, 2002; Krishnaswamy et al., 1999). CXCR2 
signaling did not influence the maturation of dendritic cells, as the stimulation of 
immature dendritic cells with CXCL8 caused no change in the expression of 
CD86, MHC II and CD83 on these cells (Feijoó et al., 2005). However, Th2 
cytokines IL-13 and IL-4 strongly induced the expression of CXCR2 on human 
dendritic cells suggesting the role of CXCL8 in intratumoral positioning at Th2 
response-dominated sites (Bonecchi et al., 2000). 
Conclusion:  
 To conclude, CXCR2 seems to play diverse roles in the pathobiology of 
the immune component of the TME ranging from chemotaxis to functional 
activation to mediating their cross talk with surrounding cells (Fig. 1.1). 
Therefore, the overall impact of inhibiting CXCR2 signaling would be cumulative 
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in terms of how an individual cell is affected and how the overall interactions 
mediated by this signaling are influenced.  
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Hypothesis and Specific Aims: 
The two major challenges faced by clinicians and researchers in PC today 
are the scarcity of early biomarkers for the detection of PC in the preinvasive 
stages and lack of proper understanding of the tumor microenvironment of PC for 
the discovery of novel therapeutic targets. Addressing these problems by specific 
research efforts may improve the prognostic outcome by enabling the targeting of 
PC in early stages and by improving the therapeutic delivery for the later stages 
of the disease.  
Oncogenic mutations in KRAS are present in 95% of PDAC cases. 
Expression of ELR+ CXC chemokines is linked to oncogenic mutations in 
different isoforms of RAS in various malignancies, for example, lung, ovarian, 
colorectal and pancreatic cancers (Ancrile et al., 2008). Of note, KRAS mutations 
are required for both initiation and maintenance of PDAC (Collins et al., 2012). 
While recent reports in PDAC have identified a KRAS-CXC chemokine link, it 
remains unclear if this signaling can serve as an early biomarker for PDAC 
progression. Reports in recent past have demonstrated the roles of CXCR2 and 
its ligands in mediating tumor-stromal interactions in PC, but the primary focus of 
these studies was endothelial cells. Nevertheless, the events regulating the 
inflammatory response and the pathological effects mediated by immune cells 
remain elusive in PC. 
Based on evidence from the literature the central hypothesis of this 
project is that CXCR2 and its ligands play important pro-tumorigenic roles during 
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a) PC initiation by mediating KRAS(G12D)-induced tumor growth and b) PC 
progression by their ability to recruit immune cells of myeloid origin (Figure 1.2).  
To test this hypothesis I pursued the following specific aims. 
Specific Aim 1: Define the role of CXCR2 in KRAS(G12D)-induced tumor growth in 
PC. 
Specific Aim 2: Evaluate the role of host CXCR2 in regulating tumor growth by 
altering the inflammatory responses in PC.  
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Figure 1.1. CXCR2 in the biology of myeloid cells. 
Schematic representation of known roles for CXCR2 in the biology of myeloid 
cells including myeloid-derived suppressor cells (MDSCs), macrophages, 
dendritic cells and mast cells. 
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Figure 1.2. Hypothesis figure summarizing the proposed roles for CXCR2 in 
pancreatic cancer. 
The central hypothesis for the research presented in this dissertation was that 
CXCR2 regulates both autocrine and paracrine mechanisms during the 
progression of pancreatic cancer (PC). Ligands produced by PC cells can bind to 
CXCR2 expressed on the surface of the tumor cells to enhance tumor cell 
proliferation. CXCR2 signaling in the host can also mediate the recruitment of 
immune suppressive cells, which can then lead to the growth of tumor cells by 
paracrine mechanisms. 
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Human pancreatic cancer specimens: 
  Tissue microarray (TMA) slides were obtained from the University of 
Nebraska Medical Center (UNMC) rapid autopsy program. TMAs were 
constructed from paraffin blocks containing tumor cores, non-cancerous 
pancreas and control specimens of gastric tissue. The study was approved by 
the Institutional Review Board of the UNMC. 
Cell line cultures and transfections: 
Cell lines and culture conditions: 
Murine cell lines. 
Panc02 cells and UN-KC-6141 cell line (Torres et al., 2013a) (referred to 
as KRAS-PDAC cells in this study, a kind gift from Dr. Surinder K. Batra’s 
laboratory at UNMC) were maintained in Roswell Park Memorial Institute Medium 
(RPMI) (HyClone®, GE Life Sciences, UT) and Dulbecco’s Modified Eagle 
Medium (DMEM) (HyClone®, Thermo Scientific, UT) respectively. These media 
were supplemented with fetal bovine serum (FBS) (Atlanta Biologicals, GA), L-
Glutamine (MediaTech, VA), two-fold vitamin solution (MediaTech) and 
Gentamycin (Gibco, Life Technologies, NY).  
Human cell lines. 
   We used a model of immortalized human pancreatic duct-derived cell 
lines, with or without exogenous expression of KRAS(G12D). The model consisted 
of four cell lines hTERT-HPNE (HPNE), hTERT-HPNE-KRAS(G12D) (HPNE-KRAS) 
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[both cell lines referred to as HPNE/-KRAS], hTERT-HPNE-E6/E7/st (E6-E7-st) 
and hTERT-HPNE-E6/E7/st/KRAS(G12D)  (E6-E7-st-KRAS) [both cell lines referred 
to as E6-E7-st/-KRAS]. Generation and maintenance of hTERT-HPNE, E6-E7-st 
and E6-E7-st-KRAS cells have been previously described (Campbell et al., 
2007).  
Transfection of murine pancreatic cancer cell lines: 
Panc02 cells: Expression of Gaussia luciferase vector. 
A lentiviral vector containing an expression cassette encoding gaussia 
luciferase (GLUC) and green fluorescent protein (GFP) was a kind gift from Dr. 
Bakhos A. Tannous, Harvard Medical School, Boston. Panc02 cells were 
transduced as described previously (Tannous, 2009). After the transduction GFP 
positive cells were sorted at the flow cytometry facility at UNMC and maintained 
in culture. 
KRAS-PDAC cells: Expression of Luciferase GFP vector. 
HEK293 cells were maintained in DMEM. The retroviral vector containing 
luciferase GFP expression was generated by infecting HEK293 cells with 
pBABE-luciferase hygromycin, pBABE-luciferase EGFP and helper virus plasmid 
(kind gifts from Dr. Kay Wagner’s laboratory, UNMC). KRAS-PDAC cells were 
transfected using CaCl2. Transfected GFP-expressing cells were flow sorted in 
the Flow Cytometry Facility at UNMC and cultured. 
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Transfections of human pancreatic cancer cell lines: 
Generation of CXCR2 knock-down cells. 
 Six human GIPZ lentiviral shRNAmir anti-CXCR2 individual clones were 
obtained from Thermo Scientific Open Biosystems (Grand Island, NY). A 
scrambled shRNA was used as a non-silencing control (NSC). Lentiviral particles 
were generated by us and cells were infected according to the manufacturer’s 
protocol.  Stable knock-down of CXCR2 was achieved in E6-E7-st-KRAS cells by 
pooling together the six different anti-CXCR2 shRNA individual clones. 
Animal models and details of in vivo studies: 
Study approval. 
   Mice were maintained under specific pathogen-free conditions. All 
procedures performed were in accordance with institutional guidelines and 
approved by the University of Nebraska Medical Center Institutional Animal Care 
and Use Committee (IACUC). 
Breeding strategy for the generation of Cxcr2-/- mice and genotyping PCR. 
 C57BL6 mice heterozygous (+/-) and knock-out (-/-) for Cxcr2 were 
obtained from Charles Rivers (Wilmington, MA). Breeding pairs used to produce 
Cxcr2-/- mice were Cxcr2-/+ female and Cxcr2-/- male (Fig. 2.1A).  All the colonies 
were maintained in the pathogen-free transgenic mouse facility at UNMC. 
Genomic DNA was isolated from tail clippings performed on 2- to 3-week-old 
mice. The tail clippings were digested overnight at 55ºC by incubating in 300 µl 
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digestion buffer containing 5 mM EDTA, pH 8.0, 200 mM NaCl, 100 mM Tris, pH 
8.0 and 0.2% sodium dodecyl sulfate (Wang and Storm, 2006). Genomic DNA 
was amplified with specific primers for wild-type Cxcr2 (forward: GGT CGT ACT 
GCG TAT CCT GCC TCAG, reverse: TAG CCA TGA TCT TGA GAA GTC 
CATG) and neomycin resistance gene (forward: CTT GGG TGG AGA GGC TAT 
TC, reverse: AGG TGA GAT GAC AGG AGA TC).  PCR amplification products 
were electrophoresed on 1.5% agarose gel containing 0.25 µg/ml ethidium 
bromide (EtBr) (Fig. 2.1B).  
Syngeneic mouse models.  
  In order to understand the role of CXCR2 in mediating the host immune 
response towards PC, we generated a syngenic immunocompetent mouse 
model having intact CXCR2 in the tumor cells and CXCR2 deletion in the tumor-
bearing host mouse. Two different murine PC cell lines Panc02-GLUC-GFP and 
KRAS-PDAC-GFP were inoculated orthotopically in the pancreas of Cxcr2+/+, 
Cxcr2-/+ and Cxcr2-/- mice, male or female, 6- to 8-week-old. Mice were sacrificed 
after 4 to 6 weeks. A part of the tumor was processed to isolate tumor-associated 
lymphocytes (TALs), and a part was fixed in 10% formalin and processed for 
histological analysis. 
Xenogenic mouse models. 
 6- to 8-week-old female nude mice were obtained from Charles River 
Laboratories (Wilmington, MA). E6-E7-st-KRAS-NSC and E6-E7-st-KRAS-
shCXCR2 cells (1 x 106 in 50 µl HBSS) were injected into the pancreas 
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(orthotopic) or flanks (subcutaneous) of nude mice.  For subcutaneous implants, 
the tumors were measured twice a week for 50 days with a caliper. The tumor 
volume was calculated using the formula: volume = (length x width2)/2. 
Subcutaneous tumors (50 days post inoculation) and orthotopic tumors (8 weeks 
post inoculation) were resected, fixed in 10% formalin and paraffin embedded.   
In vivo monitoring of growth of orthotopic tumors. 
Gaussia luciferase assay. 
  Secreted levels of GLUC were measured as described previously (Chung 
et al., 2009; Tannous, 2009). Briefly, blood was collected from the tail vein of 
mice and transferred directly to the wells of a 96-well plate containing 2 µl of 
EDTA solution. GLUC activity was measured using a plate luminometer.  
Reagents and antibodies. 
  The two CXCR2 antagonists SCH-527123 and SCH-479833 were obtained 
from Schering-Plough Research Institute and were dissolved in 20% 
hydroxypropyl-β-cyclodextrin (HPβCD) from Acros Chemical (St. Louis, MO, 
USA). All the antibodies used for the present study are listed in supplementary 
table 1. 
Gene expression analysis: 
RNA isolation. 
 Total RNA was isolated from cells and homogenized tissues using the 
standard Trizol (Invitrogen, Carlsbad, CA) protocol.  
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PCR analysis. 
  Reverse Transcription  was performed with 1-5 µg RNA using oligo (dT) 
(Fermentas, Hanover, MD, USA) and Superscript® II RT (Invitrogen) or iScript™ 
Reverse Transcription Supermix for RT-qPCR (BIO-RAD, Hercules, CA, USA). 
Regular PCR reactions were performed using Fast Start Taq dNTPack (Roche 
Diagnostics, IN, USA). Quantitative real-time PCR reactions were performed 
using FastStart SYBR Green Master Mix (Roche; Indianapolis IN, USA) using the 
MyIQ™ iCycler (BIO-RAD). Primer sets used for the study are listed in table 2.2 
and 2.3. For regular PCR, amplified cDNA was resolved on EtBr-containing 
agarose gels. For real-time PCR mean Ct values of the target genes were 
normalized to mean Ct values of the endogenous control, ribosomal protein large 
13 A (RPL13A); [-∆Ct = Ct (RPL13A) – Ct (target gene)]. The ratio of mRNA 
expression of target genes versus RPL13A was defined as 2(-∆Ct). Melting curve 
analysis was performed to check the specificity of the amplified product.  
Protein analysis: 
Protein isolation. 
 Total protein was isolated by lysing cells with RIPA buffer. Tumor tissues 
were homogenized in mammalian protein extraction reagent (M-PER®, Pierce, 
Rockford, IL). Protein concentrations were determined using BCA kit (Pierce™ 
BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). 
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Western blot analysis. 
 Protein samples (40 µg or 25 µg) were electrophoresed on sodium dodecyl 
sulfate (SDS) polyacrylamide gels (10% or 15%) and transferred onto Immobilon-
P Transfer membrane (Millipore, Billerica, Massachusetts, USA). Membranes 
were blocked with 3% BSA in PBS for 1 hour at room temperature. Membranes 
were probed with specific primary antibodies (Table 2.1) overnight at 4˚C. 
Membranes were washed with TTBS buffer, thrice and probed with respective 
secondary antibodies. Following washing with TTBS buffer membranes were 
visualized using SuperSignal® West Femto Kit (Thermo Scientific). 
Enzyme linked immunosorbent assay (ELISA). 
  Equal numbers (1 x 106) of cells CD18/HPAF-scram (control), CD18/HPAF-
shKRAS(G12D), HPNE, HPNE-KRAS, E6-E7-st, E6-E7-st KRAS,  E6-E7-st KRAS-
NSC, E6-E7-st KRAS-shCXCR2 and KRAS-PDAC cells were plated in 60 mm 
dishes in complete medium. After attachment of cells to the plate the medium 
was changed to serum free DMEM.  Supernatants of cultured cells were 
collected at 24 hours or 72 hours. ELISA assays for hCXCL8 and hCXCL1 were 
performed as described previously (Varney et al., 2011). ELISAs for hCXCL5, 
mCXCL2, mCXCL5 and mCXCL7 were performed using a duoset kit (R & D 
Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. All 
the experiments were performed in duplicate. 
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Immunofluorescence. 
  Cells were cultured on 8-well chamber slides and were allowed to adhere 
overnight. The following day, cells were fixed using 4% paraformaldehyde, 
blocked with antibody diluent (BD Biosciences), and probed with anti-CXCR2 
antibody (4˚C overnight). The next day, slides were incubated with Cy3-
conjugated anti-mouse antibody. Nuclei were counterstained with DAPI (4, 6 
diamidino-2-phenylindole). Finally, slides were mounted with Vectashield® 
mounting medium (Vector Laboratories, Burlingame, CA, USA) and observed 
under a fluorescence microscope. 
Immunohistochemistry. 
  4 µm thick, formalin-fixed, paraffin-embedded sections were deparaffinized.  
Antigen retrieval was performed using sodium citrate buffer (pH = 6.0) and 
microwaving for 10 minutes. Endogenous peroxidase was blocked by incubating 
with 3% hydrogen peroxide in methanol for 30 minutes. After blocking non-
specific binding by incubating with serum, slides were probed with primary 
antibody (Table 2.1) overnight at 4ºC. Slides were washed and appropriate 
secondary antibodies were added. Immunoreactivity was detected using the ABC 
Elite Kit and 3, 3 diaminobenzidine substrate kit (DAB) (Vector Laboratories, 
Burlingame, CA) as per the manufacturer protocols. A reddish brown precipitate 
indicated positive staining. Nuclei were counter stained with hematoxylin. For 
quantitative evaluation positive cells were counted in five independent areas at 
400X. For human PC specimens, immunostaining was evaluated by a 
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semiquantitative system. Extent (percentage of positive cells) were scored using 
the following grading system 0 (negative), 1+ (1%–10% of cells positive), 2+ 
(11%–50% of cells positive), and 3+ (>50% of cells positive). Furthermore, 
intensity was designated as weak (1 point), moderate (2 points), or strong (3 
points). IHC composite score (IHC-CS) was calculated by multiplying extent with 
intensity. 
In vitro cell based assays: 
In vitro cell proliferation assay. 
  Cells were seeded at the indicated densities in 96-well plates and were 
allowed to adhere. Cells were washed with HBSS and were incubated with 
medium alone or medium containing different serum concentrations or medium 
containing specified concentrations of the CXCR2 antagonists for 72 hours. Cell 
viability was determined by MTT assay (3-(4, 5 dimethylthiazol-2-yl)-2, 5- 
dipehnylate-tetrazolium bromide, tetrazole) as previously described (Li et al., 
2001). Percent inhibition of cell growth was calculated by the formula: [100 - 
(A/B) x 100], where ‘A’ and ‘B’ are the absorbance of the treated and untreated 
cells, respectively. Percentage of cell growth was calculated by the formula: 
[(A/B) x 100], where ‘A’ and ‘B’ are the absorbance of treatment and control 
group respectively. 
Anchorage-dependent and -independent growth assay. 
  To evaluate anchorage-dependent (clonogenic) potential, KRAS-PDAC cells 
were plated at a density of 2500 cells/well in a 6-well plate and treated with 
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different concentrations of CXCR2 antagonists in 10% DMEM. Clonogenicity was 
evaluated after ten days by fixing cells in methanol and staining with crystal 
violet.  
 Anchorage-independent growth (colony formation) was assessed by plating 
3000 cells per well in 0.3% agarose with a 0.6% agarose underlay in a 6-well 
plate. CXCR2 antagonists were added at the indicated concentrations to both 
0.3% agarose layer and the medium covering the 3% agarose layer. Cells were 
incubated for two weeks at 37º C in a 5% CO2 incubator. Media was changed 
once every week. Colonies were fixed in a solution of acetone with methanol and 
stained with 0.5% crystal violet and counted under an inverted microscope at 4X 
magnification.  
Cell migration-wound healing assay. 
 A wound healing assay was conducted to assess the migratory potential of 
the cells. Cells were plated in 60 mm dishes. After the cells reached 90-95% 
confluence, a wound was generated using 1 ml pipette tip. Cells were washed 
with HBSS and incubated with either serum-free medium or with serum free 
medium with the indicated concentrations of CXCR2 antagonists for 24 hours. 
Cells were photographed under an inverted microscope at 4X magnification at 
time T = 0 hours and T = 24 hours. The width of wound was measured using NIH 
image J software. Distance migrated was calculated by the formula: Initial wound 
width (T = 0 hours) – Final wound width (T = 24 hours).   
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Isolation of tumor-associated lymphocytes: 
 A part of the harvested tumor was digested and TALs were isolated using the 
lympholyte®-M density separation medium (CEDARLANE®, Ontario, Canada). 
TALs were further processed for RNA isolation or flow cytometry (Fig. 6.1) 
Flow cytometry: 
 In order to characterize immune cells isolated from the pancreas and spleens, 
multicolored flow cytometry was performed. Single cell suspensions were 
prepared from freshly isolated spleens by crushing them and passing the mixture 
through a cell strainer. TALs were isolated from the pancreas as described 
above. Immune cells were stained using the following antibodies: anti-CD11b 
(APC); anti-Ly6C (PE/Cy7); anti-Ly6G (Alexa Flour 700); anti-F4/80 (FITC); anti-
CD3 (FITC); anti-CD4 (PE); anti-CD8 (APC); anti-CD25 (Alexa Flour 700); anti 
CD49b (Pan-NK) (PErCP/Cy5.5) all from BioLegend® (San Diego, CA). Flow 
cytometry was performed using BDLSR II and data were analyzed with BD FACS 
DIVA and FlowJo software (Fig. 6.1).  
Statistical analysis:  
 Statistical analysis was conducted using Excel or GraphPad Prism software. 
The significance was determined by the Student’s t-test or the nonparametric 
Mann-Whitney U-test. For all statistical tests, a p-value of ≤ 0.05 was considered 
significant. 
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Figure 2.1. Breeding strategy and genotyping PCR for the generation of 
Cxcr2-/- mice. 
 A) The mouse colony was maintained by crossing Cxcr2-/- male mice with Cxcr2-
/+ female mice. B) Genotyping PCR was performed on DNA isolated from the 
snipped tails of mice. 
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Table 2.1. List of antibodies used for the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Species 
reactivity  
Antibody Supplier 
Catalogue  
number 
Host 
species 
Dilution 
Mouse mCXCR2 Kind gift from Dr. Strieter Goat 1:1000 
Mouse Gro alpha Abcam ab86436 Rabbit 1:500 
Mouse and 
human 
mCXCL3 Bioss bs-2547R Rabbit 1:500 
Mouse mCXCL5 
Cloud-clone 
corp. 
PAA860Mu01 Rabbit 1:100 
Mouse mCXCR1 
Novous 
Biologicals 
NB600-1142 Rabbit 1:100 
Human Ki-67 Santa cruz sc-15402 Rabbit 1:50 
Human 
Cleaved 
caspase 3 
Cell Signaling Asp175 Rabbit 1:200 
Mouse Cytokeratin Dako Z0622 Rabbit 1:500 
Mouse F4/80 Abcam Ab6640 Rat 1:100 
Mouse Ly6 
Thermo 
Scientific 
MA1-40038 Rat 1:50 
Human hCXCR2 Santa cruz Sc-7304 Mouse 1:200 
Human hCXCL1 Abcam Ab86436 Rabbit 1:500 
Human and 
mouse 
Erk Santa cruz Sc-94 Rabbit 1:200 
Human and 
mouse 
p-Erk Cell Signaling #9101 Rabbit 1:2000 
Human and 
mouse 
KRAS Santa cruz F234-sc-30 Mouse 1:1000 
Human and 
mouse 
Actin Sigma A2066 Rabbit 1:5000 
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Table 2.2. List of human primers used for the study 
 
                                                  
 
 
    
 
 
 
 
             
 
 
 
 
 
Human Primers 
Gene  Temperature  In this study used 
for 
Primer sequence 
CXCR2 59˚ PCR (regular) Forward-5’-ACC CAG GTG ATC CAG GAG AC-3’ 
Reverse-5’- CCA ATG AAG GCG TGA AAA GG-3’ 
RPL13A 59˚ Real-time PCR and 
regular PCR 
Forward-5’- GGCTGAAGCCTACCAGAAAG-3’ 
Reverse- 5’-CTTTGCCTTTTCCTTCCGTT-3 
59 
 
                                            
Table 2.3: List of murine primers used for the study. 
Murine Primers 
Gene Temperature 
In this study used 
for 
Primer sequence 
Cxcr2 60˚ Regular PCR 
Forward 5’- CACCGATGTCTACCTGCTGA -3’ 
Reverse 5’- CACAGGGTTGAGCCAAAAGT -3’ 
 
Cxcl1 55˚ Regular PCR 
Forward 5’-TCGCTTCTCTGTGCAGCGCT-3’ 
Reverse 5’- GTGGTTGACACTTAGTGGTCT C-3’ 
 
Cxcl2 57˚ Regular PCR 
Forward 5’-AGTGAACTGCGCTGTCAATG-3’ 
Reverse 5’-TTCAGGGTCAAGGCAAACTT-3’ 
 
Cxcl3 68˚ Regular PCR 
Forward 5’-GCAAGTCCAGCTGAGCCGGGA-3’ 
Reverse 5’-GACACCGTTGGGATGGATCGCTTT-3’ 
 
Cxcl5 68˚ Regular PCR 
Forward 5’-ATGGCGCCGCTGGCATTTCT-3’ 
Reverse 5’-CGCAGCTCCGTTGCGGCTAT-3’ 
 
Cxcl7 57˚ Regular PCR 
Forward 5’-CTCAGACCTTACATCGTCCTGC-3’ 
Reverse 5’-AGCGCAACAAGGATCGTCCTGC-3’ 
 
Ccl5 56˚ Real-time PCR 
Forward 5’-GCTGCTTTGCCTACCTCTCC-3’ 
Reverse 5’-TCGAGTGACAAACACGACTGC-3’ 
Ccl3 56˚ Real-time PCR 
Forward 5’-TTCTCTGTACCATGACACTCTGC-3’ 
Reverse 5’-CGTGGAATCTTCCGGCTGTAG-3’ 
Ccl2 56˚ Real-time PCR 
Forward 5’-TTAAAAACCTGGATCGGAACCAA-3’ 
Reverse 5’-GCATTAGCTTCAGATTTACGGGT-3’ 
IL-12 57˚ Real-time PCR 
Forward 5’-TGGGTTTGCCATCGTTTTGCTG-3’ 
Reverse 5’-ACAGGTGAGGTTCACTGTTTCT-3’ 
IL-10 57˚ Real-time PCR 
Forward 5’-GCTCTTACTGACTGGCATGAG-3’ 
Reverse 5’-CGCAGCTCTAGGAGCATGTG-3’ 
IFN-γ 57˚ Real-time PCR 
Forward 5’-ATGAACGCTACACACTGCATC-3’ 
Reverse 5’-CCATCCTTTTGCCAGTTCCTC-3’ 
TNF-α 57˚ Real-time PCR 
Forward 5’-CCCTCACACTCAGATCATCTTCT-3’ 
Reverse 5’-GCTACGACGTGGGCTACAG-3’ 
APO-2 58˚ Regular PCR 
Forward 5’ –GGATATGGCCTGGCTGTAGA-3’ 
Reverse 5’-TTGGCGGAAAGAAAGCAAGT-3’ 
Bcl2 58˚ Regular PCR 
Forward 5’-AATGTCCAGGTGGGTCAGAG-3’ 
Reverse 5’-TCCTGCTGGATCTGCCTAGT-3’ 
Bax 58˚ Regular PCR 
Forward 5’-TGCAGAGGATGATTGCTGAC-3’ 
Reverse 5’-GGAGGAAGTCCAGTGTCCAG-3’ 
Rpl13a 58˚ Regular PCR 
Forward 5’-ACTCTGGAGGAGAAACGGAAGG-3’ 
Reverse 5’- CAGGCATGAGGCAAACAGTC-3’ 
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                                                        Chapter 3 
The expression of CXCR2 and its ligands in human and murine pancreatic 
cancer  
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Abstract: 
The aim of this section of the study was to evaluate the localization of the 
expression of CXCR2 and its ligands in tissue specimens of human and mouse 
pancreatic cancer (PC). Human tissue specimens were obtained from the rapid 
autopsy program at UNMC. PC progression model was built from tumors isolated 
form Pdx1-cre;LSL-Kras(G12D) mice at different ages. Immunohistochemistry (IHC) 
for CXCR2 and its ligands was performed.  Our results demonstrate an increased 
staining for hCXCR2 and hCXCL1 and 3 in PC versus the normal pancreas. In 
the Pdx1-cre;LSL-Kras(G12D) mouse model the expression of mCXCR2 and 
ligands mCXCL1, 3 and 5 was found to be upregulated at the early stages of the 
disease. Overall, we conclude that CXCR2 and its ligands are expressed early 
during the course of PC progression. Furthermore, there expression was found to 
be located on the malignant ductal cells as well as the surrounding stroma.  
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Introduction: 
 Precise identification of the cell types expressing CXCR2 and its ligands in 
PC can help in making any targeted therapies in the future to be more accurate. 
PC is associated with a) high frequency of mutations in the KRAS oncogene in 
the malignant ductal cells and b) dense production of stroma. CXCR2 and its 
ligands are known to be expressed by several cell types in the body including 
those that are a part of the PC TME such as fibroblasts, immune cells and 
endothelial cells.  
Expression of CXCR2 and its ligands in PC cell lines has been well 
documented (Matsuo et al., 2009c; Wang et al., 2013b). Furthermore, reports in 
PC have also identified the expression of CXCR2 and its ligands CXCL8 and 5 in 
human PC patient tissue specimens (Kuwada et al., 2003; Li et al., 2011c). 
However, currently there is no study evaluating the expression of CXCL1 and 
CXCL3 in PC tissue specimens. Animal models of PC have widely expanded our 
understanding of the progression of this disease in relation to the most frequently 
mutated genes like KRAS and P53 (Hingorani et al., 2005). The Pdx1-cre;LSL-
Kras(G12D) mouse model, having pancreas specific knock-in for the Kras(G12D) 
mutation is known to closely recapitulate the histological and molecular pathology 
of the human PC (Hingorani et al., 2003a). This model enables the evaluation of 
not just the cellular pattern for the expression of molecular targets but also helps 
in identification of the time points of their expression during the course of disease 
development. However, the expression of CXCR2 biological axis during the 
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disease progression in the animal model Pdx1-cre;LSL-Kras(G12D) has not been 
reported yet.  
In order to conceive a clear picture of the probable pathological roles of 
CXCR2 and its ligands in PC we firstly evaluated the expression pattern of 
hCXCR2 and its ligands hCXCL1, 3 and 8 in the human PC tissue specimens. 
Furthermore, using pancreatic tissues derived from Pdx1-cre;LSL-Kras(G12D) 
mouse model we recognize the kinetics of their expression during the 
development and progression of PC. 
Results: 
Expression of hCXCR2 in human pancreatic cancer specimens: 
 IHC analysis revealed the presence of hCXCR2 in human PC specimens. 
We observed an intense immunoreactivity for hCXCR2 both in the ducts and the 
stroma of the human PC specimens. CXCR2 was also expressed in the normal 
pancreas; however, this expression was localized only to the acinar cell 
compartment and normal pancreatic ducts were negative for hCXCR2 expression 
(Fig. 3.1A and B). 83.33% ducts (10\12) and 88.235% stroma (15\17) in the 
primary tumors were positive for CXCR2 expression. Overall the average 
composite score of CXCR2 IHC was higher in the PC tissue specimens versus 
the normal pancreas (p = 0.075) (Fig. 3.1C).  
 
 
64 
 
Expression of hCXCL1 in human pancreatic cancer specimens: 
 Expression of hCXCL1 was detected both in the ducts and the stroma of 
human PC tissues. Normal pancreatic acinar cells also showed immunoreactivity 
for hCXCL1; however the normal pancreatic ducts were negative for its 
expression (Fig. 3.2A and B). In primary tumors, both ductal and stromal cells in 
100% specimens were positive for hCXCL1.  Overall composite score for IHC 
remained unchanged in the normal pancreas versus the PC tissue (p = 0.4211) 
(Fig. 3.2C).  
Expression of hCXCL3 in human pancreatic cancer specimens: 
 Malignant ductal cells of PC tissue and surrounding stroma showed an 
enhanced expression of hCXCL3 compared with the normal pancreas. The 
average IHC composite score for hCXCL3 was significantly higher in pancreatic 
tumors versus the normal pancreas (p = 0.049) (Fig. 3.3A and B). In normal 
pancreas the ducts were negative for hCXCL3; however, the malignant ductal 
cells showed high immunoreactivity for the ligand (Fig. 3.3C). 
Enhanced expression of CXCR2 and cognate ligands in the cancerous 
lesions of Pdx1-cre;LSL-Kras(G12D) mice. 
Earlier reports have highlighted the role of KRAS mutations in 
upregulation of CXCR2 ligands in various cancers (Ancrile et al., 2008). The 
majority of reports in PC have used in vitro cell line based model systems and 
hence the precise spatiotemporal pattern of expression of CXCR2 and its ligands 
in the context of introducing the KRAS(G12D)  mutation remains unclear (Matsuo et 
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al., 2009a). In the present study we used Pdx1-cre;LSL-Kras(G12D)   mice having 
pancreas-specific expression of the KRAS(G12D) mutation, which is known to 
recapitulate the histological and pathological features of human PDAC 
progression (Hingorani et al., 2003b). Our primary objective was to evaluate the 
cellular location and time points for the expression of CXCR2 and its ligands in 
the lesions of Pdx1-cre;LSL-Kras(G12D) mice. Pancreatic tissues derived from 
mice sacrificed at different time points (10, 25 and 50 weeks) were used to 
generate a progression model. We observed no expression of mCXCL1, 3 and 5 
in the normal pancreas, derived from the control Pdx1-cre mice. However, in 
Pdx1-cre;LSL-Kras(G12D) mice, beginning at 10 weeks of age expression of 
mCXCL1 and mCXCL3 was observed (Fig. 3.4A). This expression was further 
intensified in the tumors of mice at 25 and 50 weeks age, which represent fully 
developed PDAC. The expression was localized in both PDAC (duct) cells as 
well as the surrounding stroma. Next, we determined the expression levels of 
mCXCR2. Similar to the ligands, while normal pancreas showed no 
immunoreactivity for the protein, expression of mCXCR2 was observed in 10 
week old animals, and it further intensified in the 25- and 50- week old animals 
(Fig. 3.4A). mCXCR2 was expressed in the ducts as well as the surrounding 
stromal cells. Figure 3.4B summarizes the expression pattern of CXCR2 and its 
ligands at different time points during PDAC development. 
Discussion: 
In this section of the dissertation, we have identified the expression of the 
CXCR2 biological axis in both human and murine PC tissues and normal 
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pancreas. Our results demonstrate expression of hCXCR2 and its ligands 
hCXCL1 and hCXCL3 in the human PC tissue as well as the normal pancreas. 
However, the expression of hCXCR2 and hCXCL3 was higher in the PC tissues 
versus the normal pancreas. Furthermore, we also identified the expression of 
mCXCR2, mCXCL1, 3 and 5 in the pre-cancerous lesions of Pdx1-cre;LSL-
Kras(G12D) mice. However, unlike the human tissues the normal murine pancreas 
was negative for the expression of mCXCR2, mCXCL1 and 5. 
Previous reports have identified the expression of hCXCR2, hCXCL5 and 
8 in human PC specimens by IHC (Kuwada et al., 2003). Similar to our 
observations, expression of hCXCR2 has been reported in both PC tissues and 
normal pancreas (Oliveira Frick et al., 2008). We observed positive 
immunoreactivity for hCXCR2 only in the acinar cells of the normal pancreas; 
however, both malignant ducts and stroma were positive in the PC tissues. A 
previous report by Frick et al. demonstrated a non-significant increase in the 
expression of hCXCL1 in the PC tissues versus the surrounding normal pancreas 
(Oliveira Frick et al., 2008). We for the first time identify the expression of 
hCXCL1 using IHC analysis and demonstrate that this protein is expressed in 
malignant ductal cells and surrounding stroma of the PC tissues. We also for the 
first time identify the expression of hCXCL3 in human PC tissues. The 
expression of hCXCL3 was expressed both in the ducts as well as surrounding 
stromal compartment; furthermore, its expression was significantly enhanced 
compared with the normal pancreatic tissue.  
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Oncogenic mutations in KRAS are present in 95% of PDAC cases (Bryant 
et al., 2014). Expression of ELR+ CXC chemokines is linked to oncogenic 
mutations in different isoforms of RAS in various malignancies, for example 
lungs, ovaries, colorectal and pancreas (Ancrile et al., 2008). Of note, KRAS 
mutations are required for both initiation and maintenance of PDAC (Collins et 
al., 2012). While recent reports in PDAC have identified a KRAS-CXC chemokine 
link, it remains unclear if this signaling can serve as an early biomarker for PDAC 
progression. Using Pdx1-cre;LSL-Kras(G12D) mice as a model system we identify 
the time point of upregulation of CXCR2 signaling during KRAS(G12D)-induced 
PDAC progression. Our data provides evidence for the expression of mCXCR2 
and its ligands mCXCL1, 3 and 5 in the precursor lesions of 10-week old Pdx1-
cre;LSL-Kras(G12D) mice (PanIN-1 stage) and that their expression is further 
enhanced as these precursor lesions advanced to PDAC. Additionally, we 
identify the cellular sources for the expression of CXCR2-CXCL axis. mCXCR2, 
mCXCL1, mCXCL3 and mCXCL5 were expressed by the malignant ductal cells 
in the earliest stages and further in the stromal cells as the lesions advanced. 
The expression of mCXCR2 and mCXCL1 has been previously reported in vivo 
in tumors of Ptf1acre/+;LSL-Kras(G12D) mice (Ijichi et al., 2011a). Our results further 
elaborate these finding by identifying the spatial-temporal pattern of the 
expression of mCXCR2, mCXCL1 and two additional ligands mCXCL3 and 
mCXCL5 during the PDAC progression.  
 Taken together, we here identify the expression of CXCR2 biological axis 
in the ductal as well as the stromal compartment of PC tissues. These results 
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suggest a possible autocrine as well as paracrine roles of this signaling axis 
during PC progression. We also report the presence of CXCR2 and its ligands in 
the precursor lesions of Pdx1-cre;LSL-Kras(G12D) mice suggesting that the 
upregulation of CXCR2 biological axis is an early event during PC progression.  
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Figure 3.1. Expression of hCXCR2 in human pancreatic cancer tissue 
specimens: 
A) Representative pictures of human pancreatic cancer tissue specimens 
stained for hCXCR2. B) Higher mean composite score (extent x intensity) 
of hCXCR2 staining in human pancreatic cancer tissues (n = 17) 
compared with the normal pancreas (n = 3). Each dot on the graph 
represent composite score of one tissue specimen. C) Table summarizing 
the percent distribution of hCXCR2 staining in different cell types in normal 
pancreas and tumor tissue. Statistical significance determined by non-
parametric Mann-Whitney U test. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, NS 
p > 0.05). 
 
 
 
 
 
71 
 
 
72 
 
 
 
 
 
Figure 3.2. Expression of hCXCL1 in human pancreatic cancer tissue 
specimens.     
A) Representative pictures of human pancreatic cancer tissue specimens 
stained for hCXCL1. B) Higher mean composite score (extent x intensity) 
of hCXCL1 staining in human pancreatic cancer tissues (n = 17) 
compared with the normal pancreas (n = 3). Each dot on the graph 
represent composite score of one tissue specimen. C) Table summarizing 
the percent distribution of hCXCL1 staining in different cell types in normal 
pancreas and tumor tissue. Statistical significance determined by non-
parametric Mann-Whitney U test. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, NS 
p > 0.05). 
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Figure 3.3. Expression of hCXCL3 in human pancreatic cancer tissue 
specimens.      
A) Representative pictures of human pancreatic cancer tissue specimens 
stained for hCXCL3. B) Higher mean composite score (extent x intensity) 
of hCXCL3 staining in human pancreatic cancer tissues (n = 17) 
compared with the normal pancreas (n = 3). Each dot on the graph 
represent composite score of one tissue specimen. C) Table summarizing 
the percent distribution of hCXCL3 staining in different cell types in normal 
pancreas and tumor tissue. Statistical significance determined by non-
parametric Mann-Whitney U test. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, NS 
p > 0.05). 
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Figure 3.4. Expression of mCXCR2 and its ligands progressively increases 
in the developing cancerous lesions of Pdx1-cre;LSL-Kras(G12D) mouse 
model. A) Representative images of immunohistochemistry performed on 
progression model derived from tumors of Pdx1-cre;LSL-Kras(G12D) mice at 
different ages (n = 5 mice per group), demonstrating progressively increasing 
expression of mCXCL1, mCXCL3, mCXCL5 and mCXCR2. Normal pancreas is 
negative for the expression. B) Table summarizing the time points of expression 
of CXCR2 biological axis in Pdx1-cre;LSL-Kras(G12D) mice. 
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Abstract: 
Pharmacological inhibition of RAS, the master regulator of pancreatic 
ductal adenocarcinoma (PDAC), continues to be a challenge. Mutations in the 
various isoforms of the RAS, including KRAS, are known to upregulate CXC 
chemokines; however, their potential role in KRAS-driven pancreatic cancer 
remains unclear. In this report, we reveal a tumor cell-autonomous role of 
KRAS(G12D)-induced CXCR2 signaling in mediating  growth of neoplastic PDAC 
cells. Knocking-down CXCR2 in KRAS(G12D)-bearing human pancreatic duct 
derived cells demonstrated a significant decrease in the in vitro and in vivo tumor 
cell proliferation. Furthermore, CXCR2 antagonists demonstrated selective 
growth inhibition of KRAS(G12D)-bearing cells in vitro. Intriguingly, both genetic 
and pharmacological inhibition of CXCR2 signaling in KRAS(G12D)-bearing 
pancreatic ductal cells reduced the levels of KRAS protein, strongly implying the 
presence of a KRAS-CXCR2 feed-forward loop. Together, these data 
demonstrate role of CXCR2 signaling in KRAS(G12D)-induced growth 
transformation and progression in PDAC. 
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Introduction 
 PC is a disease with extremely poor prognosis (Siegel et al., 2015). It is 
the late clinical presentation which makes the disease extremely difficult to treat, 
leading to high mortality. Therefore, elucidating the molecular entities that 
regulate the early stages of this disease may facilitate the development of novel 
diagnostic and therapeutic strategies for PC.  PDAC is the most frequent (90%) 
histological subtype of PC. PDAC arises in a step-wise manner from precursor 
lesions, collectively known as PanINs (Vincent et al., 2011). The detection and 
targeting of PDAC at the PanIN stages may therefore provide a curative window 
for this disease. 
 The histological progression of PanINs to PDAC involves a complex 
interplay of various genetic mutations and molecular mediators. KRAS, a 
member of RAS family of GTPases, is known to be mutated in 95% cases of 
PDAC. The predominant version of this earliest tumor-promoting mutation is the 
substitution of Glycine to Aspartic acid at codon 12 (KRAS(G12D)). Inhibiting 
KRAS, the driver of PDAC development and progression, appears to be a very 
appealing approach to target the earliest stages of this disease. However, till 
date the strategies to pharmacologically block the aberrant RAS functions have 
turned futile (Bryant et al., 2014). Thus, to develop alternative approaches to 
target KRAS-induced PDAC initiation and progression it is requisite to 
understand the molecular intermediaries that execute the actions of mutant 
KRAS. 
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 Initiation and progression of cancer is intimately connected with 
inflammation. Cytokines including IL6 and ELR+ CXC chemokines are known 
targets of oncogenic RAS signaling (Ancrile et al., 2008). ELR+ CXC chemokines 
includes the ligands CXCL1-3, 5, 6, 7 and 8. A seven transmembrane G protein 
coupled receptor CXCR2 is the cognate receptor for all the ELR+ CXC 
chemokines. However, CXCL6 and 8 are also known to bind to CXCR1, having 
structural homology with CXCR2 (Chapman et al., 2009). CXCR2 signaling is 
known to contribute to tumor progression via a variety of mechanisms, including 
promoting growth of tumor cells, angiogenesis and infiltration of immune 
suppressive cells in the TME (Highfill et al., 2014; Luppi et al., 2007; Waugh and 
Wilson, 2008). Aberrant expression of CXCR2 and its ligands has been reported 
in various malignancies including cancers of lungs (Saintigny et al., 2013), 
melanoma (Wu et al., 2012), gastric (Lee et al., 2014), prostate (Salazar et al., 
2013) and pancreas (Li et al., 2011a). A higher expression of CXCL5 and CXCL8 
has been reported in patient-derived tumor samples (Li et al., 2011d; Takamori et 
al., 2000; Wente et al., 2006). In fact, CXCL5 was detected in the precursor 
PanIN lesions of human PC tissue, suggesting its role in the early stages of the 
disease (Li et al., 2011d). Also, CXCL1 and CXCL5 were found to be upregulated 
in serum samples of PDAC patients (O'Hayer et al., 2009).  With respect to 
connecting them with the RAS mutation, a recent report by Matsuo et al., 
identified KRAS(G12D) to be sufficient for the upregulation of cumulative 
expression of CXCL1, 5 and 8 (Matsuo et al., 2009a). Collectively, these reports 
identified that KRAS(G12D)-induced CXCLs play paracrine roles in mediating 
81 
 
tumor-stromal cross talk during PDAC genesis and that they do not exert 
autocrine effects in context of KRAS(G12D)-induced mitogenic growth 
transformation. Contrary to these conclusions, some of the earlier research 
efforts have indicated the role of CXCR2 signaling in mediating autonomous 
growth of tumor cells in PC. Expression of both CXCR2 and its ligands is 
detected on PC cell lines (Matsuo et al., 2009e; Wang et al., 2013a). More 
importantly, Takamorie et al., identified CXCL1 and 8 as growth factors having 
autocrine effect on the proliferation of PC cell line Capan-1, through the receptor 
CXCR2 (Takamori et al., 2000). Growth stimulatory downstream signaling of 
RAS protein is primarily mediated by the activation of ERK pathway (Thompson 
and Lyons, 2005). Interestingly, CXCR2 signaling is also known to induce 
activation of ERK pathway (Li et al., 2008). More specifically, reports in gastric 
cancer and melanoma provide evidence for the direct role of CXCL1 (a CXCR2 
ligand) in regulating the protein levels of KRAS (Cheng et al., 2011; Wang et al., 
2000). Taken together, these lines of evidence strongly support the theory that 
CXCR2 signaling might play identifiable roles in KRAS-induced autonomous cell 
growth by directly contributing to its intracellular signaling during PDAC 
development and progression.  
The objective of the current study was to shed light on the previously 
unidentified autocrine effects of CXCR2 signaling in regulating KRAS(G12D)-
induced mitogenic cell growth.  
 
 
82 
 
Results 
Expression of CXCR2 and cognate ligands in the ductal cells isolated from 
the lesions of Pdx1-cre;LSL-Kras(G12D)  mice. 
The PDAC-cell specific expression of mCXCR2 was confirmed by 
performing dual staining for cytokeratin and CXCR2. Co-localization of the two 
proteins confirmed the expression of CXCR2 in PDAC cells (Fig. 4.1A). To 
establish an in vitro system for further experimentation, we used PDAC cells 
isolated from Pdx1-cre;LSL-Kras(G12D) mice (Torres et al., 2013b). We confirmed 
the expression of transcripts of Cxcr2 and Cxcl1, 2, 3, 5 and 7 in the KRAS-
PDAC cells by PCR (Fig. 4.1B). ELISA on culture supernatants of KRAS-PDAC 
cells detected mCXCL5, which was previously detected by IHC. Furthermore, 
two additional ligands mCXCL2 and 7 were also detected (Fig. 4.1C). Expression 
of mCXCR2, mCXCL1 and 3 proteins was confirmed by immunofluoresence 
(Fig. 4.1D). Collectively, these data demonstrate that ductal cells of Pdx1-
cre;LSL-Kras(G12D) mice express mCXCR2 and its ligands. 
 KRAS(G12D) mutation-bearing human pancreatic cancer cells show higher 
expression of CXCR2 and its ligands. 
We next assessed whether KRAS(G12D)  alters  the expression of CXCR2 
and its ligands using immortalized human pancreatic ductal cells having 
exogenous expression of KRAS(G12D)  [HPNE/-KRAS  and  E6-E7-st/-KRAS]. In 
culture supernatants of both HPNE/-KRAS and  E6-E7-st/-KRAS cell line models 
we detected significantly higher expression of hCXCL1, 5 and 8 in the 
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KRAS(G12D)-bearing cells compared with their control counterparts (Fig. 4.2A and 
B). We next looked for the presence of hCXCR2 expression in both cell line 
models. The E6-E7-st-KRAS cells demonstrated upregulation of the CXCR2 
mRNA transcript in comparison to the control counterpart (Fig. 4.2C). The 
presence of CXCR2 was further confirmed by immunofluorescence, where we 
observed enhanced expression on the KRAS(G12D)-bearing cells compared with 
the control cells (Fig. 4.2D).  Further evaluation of hCXCR2 protein level by 
western blot confirmed these findings (Fig. 4.2E and F). Together, these data 
demonstrate that the KRAS(G12D) mutation directly induces the expression of 
hCXCR2 and its ligands in the PDAC cells. 
Blocking CXCR2 signaling inhibits KRAS(G12D) -induced in vitro cell growth 
and migration. 
Thus far we established the presence of the CXCR2 receptor as well as its 
ligands in KRAS(G12D)-bearing PDAC cell models. These data suggested the 
possible existence of a self-sufficient CXCR2 signaling loop on PDAC cells, 
which may act as a mediator of KRAS(G12D)-induced autocrine growth 
transformation. Based on these observations the goal of the next set of our 
experiments was to investigate whether the inhibition of CXCR2 signaling 
modulates KRAS(G12D)-induced autocrine cell growth. To investigate this, we 
generated stable CXCR2 knock-down clones of E6-E7-st-KRAS cells (Fig. 4.3A). 
Knocking down CXCR2 significantly inhibited the in vitro cell viability (Fig. 4.3B) 
and anchorage-independent growth (Fig. 4.3C). Furthermore, E6-E7-st-KRAS-
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shCXCR2 cells demonstrated markedly reduced in vitro cell migration potential 
(Fig. 4.3D).  
Next, we used a pharmacological approach to inhibit CXCR2 signaling 
using SCH-527123, a potent CXCR2 and CXCR1 antagonist. It is known to bind 
to CXCR2 at a higher affinity (picomolar) than CXCR1 (nanomolar). It has 
demonstrated  high efficacy in a variety of pulmonary inflammatory models and is 
currently in phase II of clinical trials (Chapman et al., 2009). We also used SCH-
479833, which binds to both CXCR2 and CXCR1 but is CXCR2 selective (Singh 
et al., 2009). Since RAS is a crucial signaling pathway known to regulate the 
homeostatic proliferation of normal cells, it was important for us to evaluate if the 
CXCR2 antagonists provide a selective growth disadvantage to mutant KRAS-
bearing tumor cells versus normal cells (Downward, 2003). To examine this, we 
treated our two cell models, HPNE/-KRAS and E6-E7-st/-KRAS, with the above 
mentioned CXCR2 antagonists and evaluated percent inhibition in viability at a 
time point of 72 hours. As demonstrated in fig. 4.4 A and B, at a lower dose of 
the CXCR2 antagonist there was a significant specific difference in the growth 
inhibition of the KRAS(G12D)-bearing cells versus the control cells. Furthermore, 
this difference remained even at the highest dose.  
 Taken together, these results demonstrate I) the role of CXCR2 signaling 
in KRAS(G12D)-induced autocrine cell growth and II) the specificity of CXCR2 
antagonists in facilitating  growth inhibition in  KRAS(G12D)-bearing cells versus 
the control counterparts. 
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CXCR2 knockdown in KRAS(G12D) -bearing pancreatic cancer cells affects 
tumor growth in subcutaneous and orthotopic implants. 
As a logical extension to our in vitro findings we evaluated the role of 
CXCR2 in KRAS(G12D)- induced autocrine cell growth in vivo. For the first set of 
our experiments, we performed subcutaneous injections of 1 x 106 E6-E7-st-
KRAS-NSC and E6-E7-st-KRAS-shCXCR2 cells in the flanks of nude mice and 
measured the tumors twice a week for 50 days (Fig. 4.5A). We found that the 
E6-E7-st-KRAS-shCXCR2 cells demonstrated a non-significant reduction in the 
tumor growth compared to the E6-E7-st-KRAS-NSC cells (Fig. 4.5B). Mice were 
sacrificed on day 50. We observed a decreased proliferation index and an 
enhanced apoptotic index, as observed by quantification of the IHC for Ki-67 and 
cleaved caspase3 (CC3), respectively, in the tumors from E6-E7-st-KRAS-
shCXCR2 and E6-E7-st-KRAS-NSC cells (Fig. 4.5C).  
  Subcutaneous implantation of PDAC cells can serve as advancement to 
the in vitro cell culture based studies. Yet it does not provide precise information 
as the organ microenvironment is absent and hence organ-specific responses 
cannot be evaluated. Therefore, we implanted 1 x 106 E6-E7-st-KRAS-NSC and 
E6-E7-st-KRAS-shCXCR2 cells in the pancreas of nude mice. The tumors from 
E6-E7-st-KRAS-shCXCR2 cells demonstrated inhibited proliferation and 
increased apoptotic index compared with the tumors from the E6-E7-st-KRAS-
NSC cells (Fig. 4.6).  
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Inhibiting CXCR2 signaling alters KRAS protein levels and inhibits the 
activation of the ERK pathway. 
As we observed a direct contribution of CXCR2 signaling in KRAS-
induced autocrine growth, we hypothesized that inhibition of the CXCR2 pathway 
may alter the levels of KRAS protein and activation of its downstream effectors. 
Our results demonstrate reduced protein levels of KRAS in E6-E7-st-KRAS-
shCXCR2 versus E6-E7-st-KRAS-NSC cells as evaluated by western blotting. 
Furthermore, E6-E7-st-KRAS-shCXCR2 cells showed reduced activation of the 
downstream ERK pathway, due to decreased levels of p-ERK (Fig. 4.7A). 
Treatment of E6-E7-st-KRAS(G12D) cells with increasing doses of SCH-527123 
(for 24 hours) showed a similar trend for the expression of KRAS and p-ERK 
protein in a dose-dependent manner (Fig. 4.7B). 
Discussion 
 In the present section of the study, we aimed to investigate the role of 
CXCR2 signaling in mediating KRAS(G12D)-induced autocrine growth 
transformation of PDAC cells. Our results lead us to two novel findings i) 
Upregulation of CXCR2 signaling by KRAS(G12D) enhances autonomous 
proliferation of tumor cell in PDAC; and ii) the KRAS(G12D)-induced CXCR2-CXCL  
axis in tumor cells upregulates the expression of KRAS protein maintaining a 
feed-forward loop in PDAC cells. 
Expression of CXCR2 and allied ligands was detected in the malignant 
ductal cells derived from Pdx1-cre;LSL-Kras(G12D) mice. In addition, we 
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experimentally validated the role of KRAS(G12D) in altering the expression of 
CXCR2, CXCL1, 5 and 8 in human pancreatic duct-derived cells. By expression 
of exogenous KRAS(G12D), we provide experimental evidence directly linking this 
mutation with CXCR2 signaling. A recent study by Matsuo et al. reported the role 
of KRAS(G12D)  in upregulating the cumulative expression of CXCL1, 5 and 8 in 
the E6-E7-st- KRAS cell line model (Matsuo et al., 2009a). In another report, 
knocking-down KRAS(G12D)  in a tumor derived cell line (SW1990)  down-
regulated the transcripts of CXCR2 ligands (O'Hayer et al., 2009). Our results are 
consistent with previous findings. We advance the current knowledge by 
providing the first evidence for the role of KRAS(G12D) in upregulating the 
expression of not just CXCLs but also CXCR2. We used the human pancreatic 
duct-derived hTERT-HPNE/-KRAS cell model having KRAS(G12D) as the only 
genetic alteration. As mutations in KRAS are known to occur in PanIN1 stage, 
this cell line represents the initial stages of the disease.  Consequently, based on 
these results we conclude that CXCR2 signaling axis is directly linked with the 
KRAS(G12D) and thus may contribute to the PDAC development during the initial 
stages.  
 Cancer progression involves a complex interplay of various autocrine and 
paracrine signaling pathways, which lead to the stimulation of tumor cell growth. 
RAS mutations in cancer primarily permit the uncontrolled proliferation and 
survival of tumor cells. Additionally, oncogenic RAS also induces the secretion of 
various cytokines from tumor cells that promote the tumor cell growth by altering 
the TME (Bryant et al., 2014). Previous reports implicating RAS mutations in 
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inducing the expression of CXCLs have concluded that these upregulated 
ligands fail to provoke any autonomous growth-promoting effects on the cancer 
cells and mediate paracrine effects by interacting with the TME. Using the Hela 
cell line, Sparmann and Sagi demonstrated that HRasV12-induced hCXCL8 can 
mediate tumorigenesis by enhancing angiogenesis (Sparmann and Bar-Sagi, 
2004). In ovarian cancer, HRASV12-induced upregulation of hCXCL1 was found 
to promote tumor growth through the induction of senescence in the stromal 
fibroblasts (Yang et al., 2006). Furthermore, a report in lung cancer 
demonstrated that KRAS(G12D)-induced CXCLs mediated tumorigenesis by 
recruiting inflammatory and endothelial cells (Wislez et al., 2006).  More relevant 
to the current study,  recent reports in PC have implicated KRAS(G12D)-induced 
CXCLs as mediators of angiogenesis (Matsuo et al., 2009a) or  fibrosis (Ijichi et 
al., 2011a) and noted a lack of autocrine growth-promoting effects on PC cells. 
Succinctly, the two fundamental reasons for the absence of CXCLs-mediated 
autocrine effects in all these studies were a) lack of the receptor CXCR2 on 
these cells and b) dysfunctionality of the receptor. We detected the expression of 
mCXCR2 in the KRAS-PDAC cells isolated from Pdx1-cre;LSL-Kras(G12D) mice 
and also the KRAS(G12D)-bearing human pancreatic ductal cells. Therefore, we 
were prompted to evaluate the role of CXCR2 signaling in mediating KRAS(G12D)-
induced autocrine growth transformation in PDAC. Knocking-down CXCR2 in E6-
E7-st-KRAS demonstrated a significant growth inhibition in vitro and in vivo. 
Tumors obtained from subcutaneous and orthotopic implants demonstrated 
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reduced cell proliferation and enhanced apoptosis in the shCXCR2 cells versus 
the tumors of control cells.  
Cumulatively these results clearly indicated that KRAS(G12D)-induced 
expression of CXCR2 and its ligands mediate autocrine growth transformation in 
PDAC. These results are opposite to the previous findings in PDAC. KRAS-
induced expression of CXCLs on PC cells was reported to lack an autocrine 
growth-promoting effect on PC cells (Matsuo et al., 2009a).  This inconsistency 
can be mainly explained by two facts. Firstly, they have used the HPDE cell line 
versus the HPNE cell line used in our study. Secondly, unlike the KRAS(G12D) in 
our report they have studied the effects of K-Ras4BG12V on these cells. 
Importantly, it has been reported that not all mutant KRAS proteins effect the 
downstream signaling in a similar way, which may lead to different functional 
patterns (Garassino et al., 2011). In a recent study Ijichi et al. reported that 
CXCR2 inhibition in mPanIN cell lines isolated from Ptf1acre/+;LSL-Kras(G12D) mice 
demonstrated no inhibition in cell growth (Ijichi et al., 2011a). This contrariety can 
be explained by the fact that we have cell lines isolated from Pdx1-cre;LSL-
Kras(G12D) mice, which employs a Pdx1 promoter for inducing the expression of 
KRAS(G12D) versus the Ptf1a promoter used by them. Therefore, taken together 
these findings describe a novel autocrine role of CXCR2 signaling in mediating 
KRAS(G12D)-induced cell growth in PDAC.  
Our results demonstrate that pharmacological inhibition of CXCR2 by two 
antagonists SCH-527123 and SCH-479833 (Chapman et al., 2009) engenders 
selective growth inhibition and toxicity on the KRAS(G12D)-bearing cells versus the 
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normal RAS-bearing control cells. Studies in several cancer types have 
documented anti-tumor effects of CXCR2 antagonists. We previously reported 
anti-tumor and anti-metastatic effects of CXCR2 antagonists in melanoma (Singh 
et al., 2009) and colon cancer (Varney et al., 2011) respectively. Additionally, in a 
recent study by Ning et al., SCH-527123 was shown to demonstrate in vitro and 
in vivo anti-tumor effects either alone or in combination with Oxaliplatin in colon 
cancer (Ning et al., 2012b). Also, in a proof-of-principle study on ozone-
challenged healthy human subjects, SCH-527123 was found to inhibit pulmonary 
neutrophilia. Importantly, with only a few mild adverse effects, the oral 
administration of SCH-527123 was well tolerated by human subjects (Holz et al., 
2010). By reason of information provided above, we anticipate that further 
experimenting based on results in the current study may enable the development 
of clinically effectual treatments for KRAS-induced PDAC in future.  
 The RAS protein transmits signals received from the stimulation of 
receptors on the cell surface to the nucleus via activating various signaling 
pathways. One of the key downstream mediators of RAS activation is the ERK 
pathway. The ERK pathway has been implicated in RAS-mediated autocrine and 
paracrine cell growth (Thompson and Lyons, 2005). In furtherance of 
understanding the mechanism of CXCR2 inhibition-mediated reduction in the 
KRAS(G12D)-induced growth potential of PDAC cells, we evaluated the activation 
of the ERK pathway and the total levels of KRAS. Our results demonstrated a 
marked reduction in the activation of ERK pathway, as evaluated by p-ERK 
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levels on inhibiting the CXCR2 signaling in the E6-E7-st-KRAS cells both 
genetically and pharmacologically. 
 These results are in agreement with various reports identifying CXCR2 
signaling as a regulator of the activation of the ERK pathway (Li et al., 2008). 
Importantly, in a study performed to evaluate gastric cancer metastasis, Cheng et 
al., have demonstrated that the ectopic expression of CXCL1 in the cell line 
AAZ521 enhanced the expression of NRAS and KRAS in the total cell lysates 
(O'Hayer et al., 2009). Likewise, a study in melanoma revealed elevated levels of 
KRAS and NRAS leading to an overall increase in activated RAS levels in 
CXCL1-expressing clones of immortalized murine melanocytes. These reports 
are in agreement with our results of reduction in KRAS levels by inhibiting 
CXCR2, as it is the specific receptor for CXCL1 (Waugh and Wilson, 2008). 
 Overall, our work shows for the first time the novel role of CXCR2 
signaling in mediating KRAS(G12D)-induced autocrine growth transformation of 
tumor cells by directly modulating the levels of KRAS protein and its downstream 
signaling. Figure 4.8 provides a schematic representation and summary. These 
findings may have clinical application as CXCR2 antagonists are currently in 
clinical trials for the treatment of chronic obstructive pulmonary disease. To 
conclude, these results demonstrate that targeting CXCR2 signaling might be a 
feasible approach to inhibit KRAS(G12D)-induced PDAC tumor cell growth. 
 
 
92 
 
 
  
93 
 
 
 
 
 
 
Figure 4.1. Expression of CXCR2 and its ligands in the ductal cells of 
cancerous lesions of the Pdx1-cre;LSL-Kras(G12D) mouse model. 
A) Dual immunofluorescence staining demonstrating co-localization of mCXCR2 
(Cy3) and cytokeratin (FITC) on the ductal cells. Nuclei are counterstained by 
DAPI. B) Expression of transcripts of Cxcr2 and its ligands Cxcl1, 2, 3, 5 and 7 in 
the KRAS-PDAC cells.  C) Expression of mCXCL2, 5 and 7 in culture 
supernatants of KRAS-PDAC cells, as measured by ELISA. D) 
Immunofluorescence for mCXCR2, mCXCL1 and mCXCL3 on KRAS-PDAC 
cells. Error bars represent standard error of mean.  
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Figure 4.2. The KRAS(G12D)  mutation regulates the expression of CXCR2 
and its ligands in human pancreatic cancer cells. 
 Expression levels of hCXCL1, 5 and 8 in culture supernatants of A) HPNE and 
HPNE-KRAS B) E6-E7-st and E6-E7-st-KRAS cells, as detected by ELISA. 
Values are normalized to total µg of protein. C) PCR to detect the transcript 
levels of CXCR2 in HPNE, HPNE-KRAS and E6-E7-st, E6-E7-st-KRAS cells. D) 
Immunofluorescence for CXCR2 in HPNE, HPNE-KRAS and E6-E7-st, E6-E7-st-
KRAS cells. Western blots to detect the protein levels of hCXCR2 in whole cell 
lysates of E) HPNE, HPNE-KRAS and F) E6-E7-st, E6-E7-st-KRAS. Error bars 
represent standard error of mean. Statistical significance determined by 
Student’s t test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, NS p > 0.05). 
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Figure 4.3. CXCR2 signaling mediates KRAS(G12D)-induced autocrine cell 
growth and migration. 
 A) Western blotting on total cell lysates of E6-E7-st KRAS-NSC/-shCXCR2 cells, 
demonstrating deletion of hCXCR2 at the protein level in the knock-down cells. 
B) Cell viability of E6-E7-st-KRAS-NSC/-shCXCR2 cells at different seeding 
densities at 72 hours evaluated by MTT assay C) Anchorage-independent growth 
potential of E6-E7-st-KRAS-NSC/-shCXCR2 cells was evaluated by soft agar 
colony formation assay.  D) Wound healing assay to evaluate migratory potential 
of E6-E7-st-KRAS-NSC/-shCXCR2 cells. Error bars represent standard error of 
mean. Statistical significance determined by Student’s t test (* p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001, NS p > 0.05). 
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Figure 4.4. Treatment with CXCR2 antagonist preferentially inhibits the 
growth of KRAS(G12D) mutant cells versus the control counter parts. 
Percent inhibition in cell viability of A) HPNE, HPNE-KRAS and B) E6-E7-st, E6-
E7-st-KRAS cells incubated with the indicated doses of SCH-527123 or SCH-
479833 for 72 hours.  Error bars represent standard error of mean. Significance 
of the data for each cell line was evaluated by comparing the treatment group 
with the no treatment control of the same cell line. Statistical significance 
determined by paired Student’s t test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, NS p 
> 0.05). 
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Figure 4.5. Knock-down of CXCR2 results in inhibited growth of E6-E7-st-
KRAS cells in the subcutaneous implants.  
A) E6-E7-st-KRAS-NSC and E6-E7-st-KRAS-shCXCR2 cells were engrafted 
subcutaneously in the flanks of nude mice and tumors were measured twice 
weekly. B) Tumor growth represented by change in tumor volume of 
subcutaneous tumors at indicated time points after inoculation (NS). C) 
Representative immunohistochemical (IHC) staining for Ki-67 and cleaved 
caspase3 (CC3) in tumors of mice bearing E6-E7-st-KRAS-NSC or E6-E7-st-
KRAS-shCXCR2 cells. IHC’s were quantified as the average of positive cells in 
five independent fields per tumor at 400X. Error bars represent standard error of 
mean. Statistical significance determined by paired Student’s t test (for tumor 
volume) and non-parametric Mann-Whitney U test. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.001, NS p > 0.05). 
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Figure 4.6. Orthotopic implants of CXCR2 knock-down cells demonstrate 
inhibited proliferation of tumor cells. 
Representative immunohistochemistry (IHC) images and quantified stain score 
for Ki-67 and cleaved caspase 3 (CC3). IHC’s were quantified as the average of 
positive cells in five independent fields per tumor at 400X. Statistical significance 
determined by paired Student’s t test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, NS p 
> 0.05). 
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Figure 4.7. CXCR2 regulates levels of KRAS as a feed-forward loop. 
Western blots on whole cell lysates of A) E6-E7-st-KRAS-NSC and E6-E7-st-
KRAS-shCXCR2 cells and B) E6-E7-st-KRAS cells treated with indicated doses 
of SCH-527123 for 24 hours demonstrating the protein levels of KRAS, p-ERK 
and T ERK. Actin serves as a loading control. 
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Figure 4.8. Role of CXCR2 signaling in KRAS(G12D)-induced development of 
pancreatic cancer.  
Based on data in the current study and previously published reports we can 
summarize the role of CXCR2 signaling in KRAS(G12D)-induced initiation and 
progression of pancreatic cancer as follows: A) CXCR2 and its ligands are 
induced by the point mutation (G12D) in the KRAS gene. Their expression is 
detected early and further enhances as the precursor lesions advance to 
pancreatic ductal adenocarcinoma (PDAC). B) The enhanced KRAS activity 
inside the ductal cell induces the expression of both CXCR2 and CXCLs. 
Previous reports in pancreatic cancer identify how CXCR2 ligands indirectly alter 
the tumor progression by effecting endothelial cells and fibroblasts. In the current 
study we propose a novel cell-autonomous model where these upregulated 
CXCLs bind to CXCR2 receptors on the surface of the ductal cells. This CXCR2-
CXCL autocrine loop in turn reinforces the expression of KRAS protein and 
enhances the growth of tumor cells. 
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The role of host CXCR2 in regulating the growth of pancreatic cancer 
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Abstract: 
 Pancreatic cancer (PC) is a lethal disease with an aggressive tumor 
growth and early metastasis. Dense tumor microenvironment (TME) is a 
distinguishing feature of PC. The TME is composed of a heterogeneous 
population of cells including fibroblasts, immune and endothelial cells derived 
from the host. As CXCR2 is known to be expressed by a majority of these cell 
types, we examined the role of host CXCR2 in remodeling the TME during PC 
progression. Deletion of host Cxcr2 (Cxcr2-/-) did not affect the total tumor burden 
in the mice, but did enhance liver metastasis. Furthermore, we observed 
increased apoptosis in primary tumors; however, its overall impact on tumor 
burden was neutralized by increased fibrosis in these tumors. Interestingly, 
increased fibrosis in Cxcr2-/- mice was found to be a distinct characteristic of the 
pancreatic parenchyma, as this response was not observed in subcutaneous 
tumors. Tumors from Cxcr2-/- mice demonstrated reduced angiogenesis. Spleens 
from Cxcr2-/- mice had extramedullary hematopoiesis (EMH) with specifically 
increased expansion of polymorphonuclear (myeloid precursor) cells. These data 
suggested a systemic immune suppression in the Cxcr2-/- host. Taken together, 
these findings demonstrate that host Cxcr2 signaling may contribute to PC 
progression by functioning both as a tumor promoter and suppressor.  Therefore, 
careful discretion regarding the systemic targeting of CXCR2 in PC patients is 
suggested. 
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Introduction:  
PC is the fourth leading cause of cancer-related death in both men and 
women in the USA (Siegel et al., 2015). One of the characteristic features of PC 
is the presence of a dense stromal reaction, referred to as desmoplasia, within 
the TME (Erkan et al., 2010). The contribution of TME in PC highlights the 
significance of the host responses during PC development. TME is chiefly 
composed of fibroblasts, extracellular matrix, endothelial cells and immune cells 
(Erkan et al., 2010). The overall development of PC is an outcome of the multiple 
reciprocal interactions among all these cellular entities. Therefore, in order to 
develop novel therapies for PC, it is essential to understand the role of any 
molecular marker in affecting not just the tumor cells but also the surrounding 
host milieu.   
CXCR2 and its ligands have been implicated in the regulation of tumor 
growth, angiogenesis and metastasis in various cancers (Desurmont et al., 2015; 
Sharma et al., 2015; Zhou et al., 2012). Several studies have confirmed the 
presence of CXCR2 and its ligands in human PC tissues and cell lines (Li et al., 
2011c; Matsuo et al., 2009c; Oliveira Frick et al., 2008; Wang et al., 2013b). 
Furthermore, expression of CXCR2 has been reported on PC fibroblasts (Ijichi et 
al., 2011b). CXCR2 signaling is also documented as a mediator of angiogenesis 
in PC (Ijichi et al., 2011a; Matsuo et al., 2009b; Matsuo et al., 2009c). 
Furthermore, CXCR2 is also known to orchestrate immune responses in various 
diseases including cancer (Acharyya et al., 2012; Chapman et al., 2009). Taken 
together, the literature summarized above provides evidence for the presence of 
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CXCR2 in the cellular entities of TME. Therefore, we hypothesized that CXCR2 
signaling plays a critical role in mediating tumor-stromal interactions in PC.  
 Targeting CXCR2 can have a multitude of paradoxical outcomes on the 
biology of the host. For instance, binding of a ligand to CXCR2 expressed on 
different cell types in the host including the TME might result in either redundant 
or antagonizing effects inside the tumor. In such a scenario, effective targeting of 
CXCR2 for the better therapeutic outcome can be achieved by identifying the 
specific pathological role of CXCR2 in each cellular entity of the TME. This 
approach might further enable the specific targeting of these components 
resulting in reduced side effects. In this study, we evaluated host CXCR2-
mediated effects during PC progression.  
The primary objective of the current study was to identify how host Cxcr2 
signaling alters a) pancreatic parenchyma reprogramming and b) systemic 
responses in context of developing PC. To achieve this objective, we employed a 
syngeneic immunocompetent mouse model with a Cxcr2 deletion in the host but 
intact CXCR2 expression on the tumor cells. This model enabled us to 
specifically study the role of CXCR2 inside the TME as well as its role in 
mediating systemic responses. 
Results: 
Deletion of host Cxcr2 makes no impact on tumor burden but increases 
liver metastasis. 
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 In this section of the study we sought to investigate the role of host Cxcr2 
in regulating PC tumor growth. To accomplish this objective we developed an 
immunocompetent orthotopically implanted murine model of PC. C57BL6 mice 
having WT or Cxcr2 depleted genetic background were utilized for this study. We 
used two murine cell lines for the in vivo studies: I) KRAS-PDAC cells are derived 
from the ductal lesions of Pdx1-cre;LSL-Kras(G12D)  mice. These cells express 
CXCR2 and its ligands at both mRNA and protein levels (Chapter IV). KRAS-
PDAC cells were transduced to express a GFP-firefly luciferase vector (Fig. 
5.1A). II) Panc02: CXCR2 and its ligands were detected in these cells at the 
mRNA level (Fig. 5.4A). Panc02 cells were transduced with GFP-GLUC 
expression vector (Fig. 5.4B).  
For our first experiment, KRAS-PDAC (25x104) were implanted 
orthotopically in the pancreas of WT or Cxcr2-/- C57BL6 mice. Mice were 
sacrificed after eight weeks (Fig. 5.1B). We did not observe any change in the 
tumor weight of mice with different genotypes (Fig. 5.1C). Also, there was no 
difference in the tumor incidence in mice with different genotypes (Fig. 5.1D).  
Figure 5.1E represents the histopathology of the tumors derived from mice with 
different genotypes.  
We next examined the role of host Cxcr2 in PC metastasis. KRAS-PDAC 
cells (25 x 104) were injected to the spleens of WT or Cxcr2-/- mice and liver 
metastasis was evaluated after four weeks (Fig. 5.1F). Quantitation of macro 
metastases revealed that Cxcr2-/- mice developed greater (more and larger) 
metastatic lesions in comparison to WT mice (Fig. 5.1G). To find a possible 
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explanation to this observation we evaluated the levels of CXCR2 ligands in the 
serum of tumor-bearing WT and Cxcr2-/- mice. Our results demonstrate that the 
levels of mCXCL2 were upregulated in the serum of Cxcr2-/- mice compared with 
the WT tumor-bearing mice (Fig. 5.3). Therefore, taken together we have 
observed no change in tumor burden but enhanced metastasis in the KRAS-
PDAC PC models generated by us. 
To extend our studies we used a second cell line. We implanted Panc02-
GFP cells (1x106 cells) orthotopically and detected a higher GLUC activity in the 
blood of Cxcr2-/- mice compared with the WT tumor-bearing mice (Fig. 5.4C). We 
believe that this secreted GLUC activity was representative of not just the 
primary tumor but also the metastatic burden in these mice.  
Enhanced apoptosis in tumors of Cxcr2-/- mice. 
We performed IHC for Ki-67 and CC3 on tumors derived from KRAS-
PDAC-GFP-bearing WT and Cxcr2-/- mice. We quantified the staining to evaluate 
the proliferation and apoptosis index respectively. Our data demonstrated no 
change in the proliferation index in the WT versus Cxcr2-/- mice (Fig. 5.2A). 
Cxcr2-/- mice tumors demonstrated an increased apoptosis compared with the 
WT group (Fig. 5.2B). We also determined the expression of apoptosis-related 
genes in these tumors by RT-PCR. Expression of Bcl2 (anti-apoptotic) transcripts 
were higher in Cxcr2-/- mice tumors versus the WT mice tumors whereas the 
expression of Bax (pro-apoptotic) transcripts were higher in the Cxcr2-/- host 
tumors. No change was observed in the transcript levels of Apo-2 in the two 
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groups (Fig. 5.2C). We also observed similar results in the Panc02 PC model 
(Fig. 5.4D and E). Collectively, these data show that host CXCR2 signaling does 
not affect tumor cell proliferation but supports tumor growth by inhibiting tumor 
cell apoptosis. 
Alteration of stromal responses in the tumor microenvironment of Cxcr2-/- 
hosts. 
 After identifying the overall impact of deleting host Cxcr2 on tumor growth, 
we next wanted to gain an insight into the role of CXCR2 signaling in regulating 
the characteristic stromal responses in PC. Therefore, we evaluated 
angiogenesis and fibrosis in these tumors. Figure 5.5A shows the representative 
photomicrographs of Masson’s trichrome staining on tumors. Quantitation of the 
blue stain in arbitrary units revealed that Cxcr2-/- hosts have higher fibrosis in the 
TME (Fig. 5.5A). We evaluated the vessel density by performing IHC for CD31. 
Our data shows that Cxcr2-/- mice demonstrate significantly inhibited tumor 
angiogenesis (Fig. 5.5B). 
Different effect of host Cxcr2 deletion on the fibrotic response in orthotopic 
versus subcutaneous tumors. 
 The organ microenvironment itself can be an important determinant in 
regulating desmoplasia in PC. In order to evaluate whether CXCR2 signaling has 
any role in regulating the organ-specific response in PC, we implanted KRAS-
PDAC (25x104) cells subcutaneously in WT or Cxcr2-/- C57BL6 mice. 
Interestingly, our data demonstrated that when PC cells were implanted 
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subcutaneously there was a reduction in tumor weight (Fig. 5.6A) and 
proliferation (Fig. 5.6C) in Cxcr2-/- hosts compared with WT. Furthermore, unlike 
the orthotopically implanted tumors, we observed no change in the fibrosis in the 
tumors derived from animals with different genotypes (Fig. 5.6D). These results 
indicate that deletion of host Cxcr2 exerts organ-specific variations in the 
fibroblasts of the TME.  
Increased accumulation of immature myeloid precursors in the spleens of 
tumor-bearing Cxcr2-/- mice. 
 Gross anatomical evaluation of spleens derived from tumor-bearing mice 
demonstrated increased spleen size (Fig. 5.7A) and weight (splenomegaly) (Fig. 
5.7B) in the Cxcr2-/- mice versus the WT mice. Histopathological evaluation of 
H&E stained spleens of tumor-bearing mice by a pathologist showed higher EMH 
in the spleens of Cxcr2-/- mice versus the WT genotype. Furthemore, WT and 
Cxcr2-/- mice showed differences in the ratios of the expanding populations. 
Inside the follicular zone in the spleens of WT tumor-bearing mice the ratio of 
myeloid to erythroid and lymphoid precursors was 1:3. However, in Cxcr2-/- 
tumor-bearing mice the follicular zones showed much higher expansion of 
immature myeloid precursor cells with a myeloid to erythroid and lymphoid 
precursors ratio of 3:1 (data not shown). Hema3 staining on splenocytes 
demonstrated an enhanced accumulation of polymorphonuclear cells in the 
spleens of Cxcr2-/- tumor-bearing mice compared with the WT tumor-bearing 
group. It is important to note that non-tumor-bearing Cxcr2-/- mice also have 
116 
 
increased populations of polymorphnuclear cells versus the WT mice. However, 
their accumulation is highest in the tumor-bearing Cxcr2-/- group (Fig. 5.7C).  
Discussion: 
 The primary objective of this study was to identify the role of CXCR2 
signaling in the PC TME. Our results demonstrate that deletion of host Cxcr2 did 
not reduce the tumor burden despite enhancing apoptosis in orthotopic PC 
tumors. We believe that enhanced fibrosis in the tumors of Cxcr2-/- hosts limits 
the overall cell burden reduction thus reducing the impact caused by Cxcr2 
deletion. Importantly, enhanced fibrosis was not observed in tumors when 
inoculated subcutaneously, highlighting the specific role of CXCR2 signaling in 
the pancreatic parenchyma. Angiogenesis was significantly inhibited in tumors 
implanted in Cxcr2-/- mice. Furthermore, Cxcr2-/- mice had increased liver 
metastasis. These mice also demonstrated systemically enhanced expansion of 
myeloid progenitors in the spleens. Taken together, based on these results we 
conclude that deleting host Cxcr2 causes both tumor-inhibiting and tumor-
promoting effects. 
Our first objective was to assess how the deletion of Cxcr2 in the tumor-
bearing host impacts the growth of tumor cells with intact CXCR2 signaling.  Our 
results show that host Cxcr2-/- had no effect on the size of orthotopic tumors but 
enhanced metastatic dissemination of tumor cells. Further analysis revealed that 
abrogation of Cxcr2 in the tumor parenchyma did not affect the proliferation of 
tumor cells but did enhance their apoptosis. These results suggest that host 
Cxcr2 regulates the growth of tumor cells mainly by inhibiting apoptosis in them. 
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Recent research has shown that inhibiting Cxcr2 in tumor-bearing host can either 
promote or inhibit the growth of PC tumors (Li et al., 2011b; Matsuo et al., 
2009e). Treatment with a neutralizing anti-mouse CXCR2 antibody significantly 
reduced tumor volume, proliferation and angiogenesis in an orthotropic xenograft 
mouse model of PC (Matsuo et al., 2009e). Furthermore, in another report Li et 
al. showed that orthotopic inoculation of syngenic cells in mice with a Cxcr2 
deficient background led to reduced tumor volume (Li et al., 2011b). Contrary to 
these observations, a recent review by Hertzer et al. discussed unpublished data 
supporting our observations. They observed larger tumors in Cxcr2-/+ mice 
versus the WT. Similarly, they also observed larger tumors in an orthotopic 
xenograft rodent model treated with the CXCR2 antagonist Reparixin (Hertzer et 
al., 2013). In the current study we observed no change in the overall size of the 
tumor but enhanced disease burden due to increased liver metastasis in Cxcr2-/- 
mice compared with WT.  
To gain insight into the role of CXCR2 in regulating the characteristic 
stromal responses in PC we evaluated angiogenesis and fibrosis. Tumors from 
Cxcr2-/- mice had increased fibrosis and reduced angiogenesis. Interestingly, in 
the subcutaneously inoculated PC cells, Cxcr2 deletion in the host did not affect 
the fibrosis. This observation strongly suggested a pancreatic parenchyma 
specific role of CXCR2 in regulating the fibrotic response in tumors. Expression 
of CXCR2 has been reported on PC fibroblasts (Ijichi et al., 2011b). In a recent 
report, Takamori et al. demonstrated that subcutaneous implants of a mixture of 
PC cells with fibroblasts showed faster tumor growth compared with only PC 
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cells. More importantly, CXCR2 knock-down in fibroblasts inhibited subcutaneous 
tumor growth while CXCR2 knock-down in the tumor cells caused no effect 
(Takamori et al., 2000). In the current study we demonstrate for the first time the 
impact of deleting CXCR2 in fibroblasts in vivo, inside the surrounding organ 
microenvironment. Furthermore, we also compared the effect of host Cxcr2 
deletion on tumors implanted orthotopically versus subcutaneously. This 
approach helped us to identify the role of CXCR2 in fibroblasts that is unique to 
the pancreatic parenchyma and how it alters the tissue programming in response 
to PC. Our results led us to the conclusion that CXCR2 is a negative regulator of 
fibrosis in pancreatic tumors.  
The CXCR2 signaling axis has been well appreciated for its role in 
mediating angiogenesis in various cancers including PC.  Moritz et al. reported 
the angiogenic activity of CXCR2 in PC by evaluating angiogenesis induced by 
culture supernatants of PC cell lines in vivo using the corneal micropocket assay 
(Wente et al., 2006). A recent study by Li et al. reported that tumor-bearing 
Cxcr2-/- mice demonstrated a reduction in the levels of bone marrow-derived 
endothelial progenitor cells (EPCs) in bone marrow and blood. Congruent with 
this observation, the authors show that CXCR2 knock-out reduced the 
proliferation and capillary tube formation of bone marrow derived cells in vitro (Li 
et al., 2011a). Our observation of reduced angiogenesis in Cxcr2-/- mice is in 
accordance with the aforementioned reports. However, the overall impact of 
reduced angiogenesis and enhanced fibrosis on tumor progression is hard to 
119 
 
predict as PC is known to be hypo vascular (Feig et al., 2012)   and fibrosis is 
currently an area of contention in PC (Özdemir et al., 2014). 
One of the key findings of this section of the study was enhanced EMH 
resulting in the accumulation of immature polymorphonuclear cells in the spleens 
of Cxcr2-/- tumor-bearing mice. Based on this observation we hypothesize that 
CXCR2 deficiency in host may lead to systemic immunosuppression. EMH has 
been identified in cancer patients. EMH is important for the increased demand of 
TALs in cancer (Cortez-Retamozo et al., 2012). A recent study demonstrated that 
splenectomy can delay the tumor growth in the KP model of lung cancer (Cortez-
Retamozo et al., 2012). This study identified extramedullary stem and progenitor 
cells as targets of drug therapy (Cortez-Retamozo et al., 2012). EMH can result 
from the switching on of dormant hematopoietic precursor stem cells in the 
spleens or can be a secondary phenomenon following the filtration of 
hematopoietic precursor cells into the spleens (Conor O'keane et al., 1989). 
Cxcr2-/- mice have been shown to have expansion of myeloid progenitor cells in 
spleens, blood and bone marrow (Rollins, 1999). Therefore, we concluded that it 
is important to evaluate the dynamics of immune responses in spleens and inside 
the tumors of host Cxcr2-/- PC model generated by us. 
Taken together, these data reveal novel roles of CXCR2 in mediating host 
responses during the development of PC. The model system employed by us 
illustrates the impact of the absence of CXCR2 signaling in the entire host 
compartment. This model helped us to identify the cumulative effect of Cxcr2 
depletion in host. Further experimentation in an advanced model systems can 
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help refine the information generated in this study. For instance, in future studies 
employment of mouse models with Cxcr2 depletion in specific host cellular 
compartments can help identify the most suitable target cell(s) for inhibiting 
CXCR2 signaling in PC. 
 
                                                         
 
 
 
 
 
 
 
 
 
 
 
121 
 
 
 
122 
 
 
 
 
Figure 5.1. Deletion of host Cxcr2 does not affect tumor growth but 
enhances liver metastasis.  
A) Representative photographs showing expression of GFP in transduced 
KRAS-PDAC-GFP cells. B) Intravital luciferase images demonstrating the 
development of orthotopic tumors in wild type (n = 9) and Cxcr2-/- (n = 8) mice 
inoculated with KRAS-PDAC-GFP cells. C) Weight of tumors harvested from wild 
type and Cxcr2-/- mice. Each dot on the graph represents data point from an 
individual animal. D) Tumor incidence in wild type and Cxcr2-/- mice. E) 
Representative photographs of H&E staining showing the histopathology of 
tumors. F) A schematic depicting the procedure of the experimental metastasis 
assay. G) Representative images of H&E staining of livers demonstrating 
metastatic lesions in livers and corresponding graphs quantitating metastasis in 
wild type and Cxcr2-/- mice. Error bars represent standard deviation.  
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Figure 5.2. Knock-out of host Cxcr2 enhances apoptosis in tumors.  
Representative photographs at 400X and graphs representing quantitation of A) 
Ki-67 and B) Cleaved caspase 3 (CC3) immunohistochemical staining. Each dot 
on the graph represents data point from an individual animal. Error bars 
represent standard deviation. C) PCR showing expression of Apo2, Bcl2, Bax 
and Rpl13a mRNA in tumors.  
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Figure 5.3. Deletion of host Cxcr2 enhances serum levels of mCXCL2. 
Expression levels of A) mCXCL2, B) mCXCL5 and C) mCXCL7 in serum of 
tumor-bearing wild type and Cxcr2-/- mice. Error bars represent standard 
deviation.  
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Figure 5.4. Growth of Panc02 tumors in Cxcr2-/- mice. 
A) Detection of Cxcl2, Cxcl3 and Cxcl5 in Panc02 cells by RT-PCR B) 
Representative images of Panc02 cells transduced with GLUC-GFP C) Higher 
GLUC activity in the blood of Panc02 tumors in Cxcr2-/- versus the wild type mice. 
Representative photographs of immunohistochemical staining and quantitative 
graphs of D) Ki-67 and E) Cleaved caspase 3 (CC3). Error bars represent 
standard error of mean. 
 
 
 
 
 
 
 
129 
 
 
 
 
 
 
 
 
 
 
 
 
130 
 
 
 
 
 
Figure 5.5. Increased fibrotic response and decreased angiogenesis in 
tumors of Cxcr2-/- mice.  
A) Photomicrographs demonstrating Masson’s trichrome staining for the 
assessment of fibrosis in wild type and Cxcr2-/- tumor-bearing mice and graph 
quantitating the extent of blue staining in arbitrary units B) Representative 
photographs of immunohistochemical staining for CD31 and quantitation for 
evaluating the microvessel density. Each dot on the graph represents data point 
from an individual animal. Error bars represent standard deviation. Statistical 
significance determined by paired Student’s t test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.001, NS p > 0.05). 
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Figure 5.6. Host Cxcr2 depletion inhibits the growth of pancreatic cancer 
cells at ectopic sites.  
A) Weight of tumors (gms) developed by subcutaneous inoculation of KRAS-
PDAC-GFP cells in wild type and Cxcr2-/- mice. B) H&E stained sections of 
subcutaneous tumors from wild type and Cxcr2-/- mice. C) Representative 
pictures of immunohistochemistry for Ki-67 (400X) and its quantitation. D) 
Photomicrographs of Masson’s trichrome staining for assessment of fibrosis in 
wild type and Cxcr2-/- tumor-bearing mice. Each dot on the graph represents data 
point from an individual animal. Error bars represent standard deviation. 
Statistical significance determined by paired Student’s t test (* p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001, NS p > 0.05). 
. 
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Figure 5.7. Splenomegaly in Cxcr2-/- tumor-bearing mice.  
A) Representative images of spleens resected from tumor-bearing wild type 
and Cxcr2-/- mice.  B) Increased spleen weight in the tumor-bearing Cxcr2-
/- mice versus the wild type group. Each dot on the graph represents data 
point from an individual animal. C) Representative pictures of Hema3 
staining of cytospins prepared from the splenocytes of wild type and 
Cxcr2-/- non-tumor-bearing and tumor-bearing mice.   
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Chapter 6 
CXCR2 biological axis in regulating host immune responses to pancreatic 
cancer 
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Abstract: 
 The presence of immunosuppressive cells inside the tumors as well as 
systemically in pancreatic cancer (PC)-bearing host is well documented. 
However, mechanisms regulating these immune responses remain unclear. In 
the previous chapter, we demonstrated that Cxcr2 deletion in host leads to 
extramedullary hematopoiesis (EMH) and specific expansion of myeloid 
precursor cells in the spleens. Our objective for this section of the study was to 
elaborate the role of CXCR2 in regulating the dynamics of immune responses 
both locally (inside tumors) and systemically in PC. A higher intensity of CXCR2 
was observed on MDSCs and dendritic cells located in the tumors versus the 
spleens. Deletion of host Cxcr2 resulted in an enhanced accumulation of MDSCs 
in the spleens but inhibited their recruitment to the tumors. This altered dynamics 
of MDSCs was paralleled by increased frequency of cytotoxic T cells inside the 
tumors. Spleens in Cxcr2-/- mice demonstrated reduced cytotoxic T cells to 
MDSC ratio, suggesting a systemic immune suppression in Cxcr2-/- hosts. We 
also observed an increased accumulation of the antigen-presenting dendritic cell 
populations inside the tumors. Also, the changes in the levels of cytokines were 
evaluated in the immune cell populations inside the tumors of Cxcr2-/- hosts. 
Overall, this study for the first time defines the role of CXCR2 in altering the 
landscape of immune responses in PC.  
  
137 
 
Introduction: 
The immune system in PC patients is severely impaired (Clark et al., 
2007b). PC tumors are known to contain infiltrates of immune cells that help to 
suppress the anti-tumor responses (Clark et al., 2007c; Evans and Costello, 
2012; Wörmann et al., 2014). Such immune infiltrates are composed of both 
myeloid- and lymphoid- lineages that include MDSCs, macrophages and Tregs 
(Wörmann et al., 2014). Apart from the local immune suppression at the tumor 
sites, immune responses in PC are also known to be ineffective systemically (von 
Bernstorff et al., 2001). In cancer patients, spleens are known to serve as 
reservoirs for tumor-associated immune cells and EMH (Cortez-Retamozo et al., 
2012). By continuous proliferation of splenic hematopoietic stem cells, the 
constant demand of TALs is met (Cortez-Retamozo et al., 2012). Tumor-released 
factors in cancer stimulate myelopoiesis but block the differentiation of immature 
myeloid cells (IMCs) to mature myeloid cells like macrophages, dendritic cells 
and granulocytes. This IMC population is further activated by another group of 
factors resulting in the generation of immunosuppressive cells collectively known 
as MDSCs. MDSCs are known to have increased levels of ROS, arginase, 
and/or NO (Gabrilovich and Nagaraj, 2009).  A spontaneous murine model of PC 
was shown to have a significant accumulation of MDSCs in their spleens at 
PanINs and PDAC stages (Clark et al., 2007c). Therefore, the authors suggested 
that MDSCs in PC are expanded systemically and recruited to the sites of 
tumors. It is important to note that MDSCs have the ability to cause immune 
suppression both locally and systemically (Nagaraj and Gabrilovich, 2008). 
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These findings implicate MDSCs as one of the key cells involved in systemic 
immune suppression in PC.  
In order to develop effective immunotherapies for PC, it is important to 
shed light on mechanisms that are involved in regulating the production of 
immune cells as well as their relocation to the tumors. In PC mechanisms 
controlling these alterations are not yet elaborated. CXCR2 can be an important 
target for immunotherapy in light of the numerous scientific reports identifying 
CXCR2 as a key regulator of immune responses in several diseases (Chapman 
et al., 2009) including cancer (Highfill et al., 2014; Katoh et al., 2013). 
In the previous chapter, we demonstrated that deletion of CXCR2 in the 
host resulted in no effect on the size of the primary tumor but enhanced the 
metastatic burden in these mice. We also observed altered hematopoietic 
responses in the Cxcr2-/- host at the spleens. Therefore, in this section of the 
study our objective was to evaluate how CXCR2 regulated immune responses 
contribute to the tumor-associated phenotypes in PC. 
Results: 
 CXCR2-positive myeloid cell populations are present in the pancreas and 
spleens of tumor-bearing mice.  
 CXCR2 is known to be expressed by myeloid cell populations including 
macrophages, MDSCs, mast cells and dendritic cells. We identified the presence 
of CXCR2+ MDSCs, macrophages and dendritic cells in the syngeneic orthotopic 
PC murine model generated by us. To evaluate the significance of CXCR2 in the 
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recruitment of myeloid cell populations the tumors, we firstly we examined the 
intensity of CXCR2 expression on immune (myeloid-lineage) cells located in the 
tumors versus similar cells in spleens. Our results demonstrates that the intensity 
of CXCR2 expression is higher in MDSCs (CD11b+Ly6C+G+), macrophages 
(CD11b+F480+) and dendritic cells (CD11b+) located in tumors versus the 
spleens (Fig. 6.2A and B). These data suggest that CXCR2 signaling is likely to 
mediate the infiltration of these immune populations from spleens to the tumor 
site. 
Depletion of host Cxcr2 inhibits the infiltration of MDSCs to the tumors but 
causes their splenic expansion. 
 We next assessed the frequencies of myeloid cell populations in the 
tumors and spleens of tumor-bearing WT and Cxcr2-/- host mice. We firstly 
evaluated the frequency of MDSCs, macrophages and dendritic cells in tumors of 
WT versus Cxcr2-/- hosts. As illustrated in (Fig. 6.3A and 6.4A), we observed 
that Cxcr2-/- in the hosts decreased the frequency of MDSCs inside the tumors. 
We found no change in the infiltration of macrophages (Fig. 6.3B and 6.4B). 
However, the frequency of dendritic cells was increased in tumors of Cxcr2-/- 
hosts (Fig. 6.3C). These results suggest that while CXCR2 mediates the 
recruitment of MDSCs to the tumors, it does not seem to be the central player in 
the recruitment of macrophage population. Furthermore, Cxcr2-/- may also cause 
the sequestration of antigen-presenting dendritic cells in the tumors. 
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 In the previous chapter, we showed that the Cxcr2-/- mice have larger 
spleens versus WT tumor-bearing mice. Spleens are known to be sites of EMH 
and serve as reservoirs for supplying TALs in cancer. Therefore, we evaluated 
the alterations in the frequencies of myeloid cell populations inside the spleens of 
Cxcr2-/- tumor-bearing hosts. Our data demonstrated that Cxcr2 deletion 
increased the frequency of MDSCs inside the spleens (Fig. 6.3D and 6.4C and 
D); however, we observed no change in the frequencies of macrophages (Fig. 
6.3E) and dendritic cells (Fig. 6.3F) in the spleens.  
Host Cxcr2 depletion increases the cytotoxic T cell frequency inside the 
tumors but decreases the same inside the spleens. 
 We evaluated the effect of deleting host Cxcr2 on the populations of T cell 
subsets in the TME. We observed that the tumors in Cxcr2-/- mice demonstrated 
increased populations of  T helper (Th) cells (CD3+CD4+CD25-) and cytotoxic T 
cells (CD3+CD4-CD8+) cells versus the WT group (Fig. 6.5A). We also 
evaluated the effect of Cxcr2 deletion on the population of Treg cells (CD3+CD4-
CD25+). Cxcr2-/- mice demonstrated inhibition in the recruitment of 
immunosuppressive Treg population (Fig. 6.5A). In spleens we observed no 
change in the frequency of Th cells (CD3+CD4+CD25-) (Fig. 6.5B). The 
frequencies of cytotoxic T cells (CD3+CD4-CD8+) were lower in the spleens of 
Cxcr2-/- tumor-bearing mice (Fig. 6.5B). No alteration in the population of Treg 
cells (CD3+CD4-CD25+) was observed inside the spleens (Fig. 6.5B).  
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To further elaborate our data we calculated the ratio of cytotoxic T cells to 
MDSCs in tumors as well as the spleens. We found that the ratio of cytotoxic T 
cells to MDSCs increased in the tumors of Cxcr2-/- mice suggesting that these 
tumors demonstrate enhanced anti-tumor immunity (Fig. 6.6A). However, this 
ratio was reduced in the spleens of Cxcr2-/- tumor-bearing hosts (Fig. 
6.6B).These results support our hypothesis of systemic inhibition in the Cxcr2-/- 
hosts. 
Host Cxcr2 depletion alters the levels of cytokines in tumor-associated 
lymphocytes and the spleens. 
As a next step, we evaluated the alterations in the gene expression of 
cytokines in the TALs isolated from WT and Cxcr2-/- tumors. The TALs isolated 
from Cxcr2-/- mice demonstrated enhanced expression of Ccl2, 5 and 3 (Fig. 
6.7A). Furthermore, the expression of TNF-α, cytotoxic T cell effector cytokine 
IFNγ and its inducer IL-12 was increased in the Cxcr2-/- TALs population (Fig. 
6.7B).   
Discussion: 
 In the current section, we aimed to establish the role of CXCR2 biological 
axis in regulating the host immune responses to PC. We examined the effect of 
Cxcr2 ablation in the host on intratumoral and systemic immune responses 
during PC progression. Based on our results we conclude that CXCR2 
differentially regulates immune responses to PC inside the tumors versus 
peripherally in the host system. Our findings in favor of this notion are as follows: 
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i) Impaired recruitment of MDSCs and Tregs in the tumors of Cxcr2-/- mice.  ii) 
Increased recruitment of cytotoxic T cells in tumors of Cxcr2-/- hosts. iii) Splenic 
accumulation of MDSCs in the Cxcr2-/- hosts. iv). Decreased cytotoxic T cells/ 
MDSCs ratio in the spleens. Taken together, these findings elaborate a novel 
role of CXCR2 in regulating local and systemic immunological mechanisms in 
PC. 
 One of the key findings of this study was the inhibited recruitment of 
MDSCs to the tumors of Cxcr2-/- hosts and their paralleled expansion in the 
spleens. In the previous chapter we observed identical results of increased 
splenic accumulation of immature polymorphonuclear (myeloid) cell populations 
in the Cxcr2-/- hosts. Our findings in this section have refined our knowledge from 
the previous chapter by confirming the phenotype of these cells as MDSCs 
(CD11b+ Ly6C+Ly6G+). MDSCs are a phenotypically heterogeneous population 
of immature myeloid cells. MDSCs are known to express CXCR2 and several 
studies have elaborated the role of CXCR2 signaling axis in MDSC trafficking in 
various cancers including breast (Acharyya et al., 2012), colon (Katoh et al., 
2013) and rhabdomyosarcoma (Highfill et al., 2014). Resembling our observation 
of higher CXCR2 intensity on Ly6G-C populations in tumors versus in spleen, a 
report in melanoma identified higher levels of chemokines CXCL1-3, 5, 7 and 8 
on MDSCs located in tumors compared with the MDSC population in bone 
marrow (Wang et al., 2015). More importantly recent report by Highfill et al. also 
demonstrated similar results that CXCR2 deficiency inhibited the granulocytic 
MDSCs trafficking to the tumors in murine rhabdomyosarcoma resulting in their 
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compensatory accumulation in the spleens and blood stream. They further 
concluded that CXCR2+ granulocytic MDSCs mediate local immunosuppression 
in murine rhabdomyosarcoma and inhibiting CXCR2 signaling can enhance the 
efficacy of checkpoint inhibitors (Highfill et al., 2014). Collectively, our data 
clearly demonstrates that CXCR2 is essential for the migration of MDSCs from 
the spleens to the tumors in PC. Furthermore, we also show that inhibition of 
host Cxcr2 causes the systemic expansion of MDSCs in the spleens of tumor-
bearing hosts. 
 We observed no effect of host Cxcr2 ablation on the recruitment of 
macrophages. These observations are in agreement with previous reports 
demonstrating no effect of CXCR2 activation on monocyte chemotaxis (Bailey et 
al., 2007). Another detrimental effect of host Cxcr2 depletion on tumor 
progression can be mediated by dendritic cell’s sequestration. We observed 
higher frequency of dendritic cell populations in the tumors, which suggest a 
possible sequestration of these cells inside the tumors resulting in poor antigen 
presentation and impediment of dendritic cell activated anti-tumor T cell 
responses (Feijoó et al., 2005). Thus, our data suggests that there can be a 
number of mechanisms that can compensate for the anti-tumor effect caused by 
reduced infiltration of MDSCs to the tumors of Cxcr2-/- hosts. 
 As we found an altered frequency on MDSCs in the tumors and spleens of 
Cxcr2-/- hosts, we were prompted to next examine the effect of Cxcr2 deletion on 
the frequencies of various T cell populations both in spleens and tumors. Clark et 
al. (2007) provided a direct evidence for the role of MDSCs in regulating T cell 
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responses. They demonstrated that lack of tumor-infiltrating effector T cells 
strongly correlated with the presence of intratumoral MDSCs (Clark et al., 
2007b).   Also, MDSCs are also known to cause indirect immunosuppression by 
promoting the recruitment of Tregs and by blocking the entry of effector T cells to 
the tumor sites (Goedegebuure et al., 2011). Matching our hypothesis, we 
observed an increased ratio of cytotoxic T cells to MDSCs in the pancreas and 
decreased frequency of Tregs. Conversely, in spleens the ratio of cytotoxic T 
cells to MDSCs was reduced. MDSCs are known to suppress the proliferation 
and activation of T cells by inhibiting the expression of  MHC class II on antigen 
presenting cells and CD3-ζ chains on T cells respectively, primarily by the 
production of iNOS and arginase 1 (Fujimura et al., 2010; Gabrilovich and 
Nagaraj, 2009; Goedegebuure et al., 2011; Nagaraj and Gabrilovich, 2008). 
However, in the peripheral tissues MDSCs function as antigen-presenting cells 
and induce ROS-mediated T cell suppression during the antigen specific 
interaction between MDSCs and T cells (Nagaraj and Gabrilovich, 2008). Thus, 
these findings suggested a systemic immune suppression in the Cxcr2-/- hosts.  
 Cytokines are important for mediating the communication and action of 
immune cells and mounting the inflammatory immune responses to tumors 
(Candido and Hagemann, 2013). Therefore, we evaluated the alteration in the 
cytokine profile of TAL’s. Cytokines are known to play dual roles in tumor biology 
(Burkholder et al., 2014). Our data demonstrate that Cxcr2-/- TALs have 
enhanced expression of transcripts of IL-12, IL-10, IFNγ and TNFα. IFNγ is 
essential for antigen-specific immune responses of CD4+ Th and CD8+ cytotoxic 
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T cells (Burkholder et al., 2014).TNFα is known to mediate the recruitment and 
cytotoxic activation of CD4+ T cells (Burkholder et al., 2014). We also observed 
an increased transcript expression of Ccl2, 3 and 5. These chemokines have 
been implicated for their roles in the recruitment of T cells to tumors (Lança et al., 
2013). 
Based on these data, we postulate that although Cxcr2 deletion in the host 
inhibits the recruitment of MDSCs to the tumors yet it causes the expansion of 
MDSC populations in the spleen leading to systemic immune suppression in 
these mice. This systemic immunosuppression caused by the accumulation of 
MDSCs in Cxcr2-/- mice compensates for the tumor-inhibitory effect of decreased 
trafficking of MDSC populations to the tumors.  Our study provides an overview 
of the novel roles of CXCR2 altering the landscape of host immune responses to 
the PC. However, we have employed an orthotopically implanted PC murine 
model generated by surgeries. Also, all the data for alterations in the frequencies 
of immune cells presented by us did not reach statistical significance. Further 
experimenting in spontaneous PC murine models may help in refining the results 
generated in this study.  
 
 
 
 
146 
 
 
 
147 
 
 
 
 
 
 
 
 
Figure 6.1. Outline of the experimental approach used to characterize 
infiltrating immune cells.  
Schematic representation of the experimental approach and the details of 
markers employed to characterize the immune infiltrates by flow cytometry. 
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Figure 6.2. The intensity of CXCR2 on the myeloid cell population in 
spleens versus the pancreas.  
A) Comparison of the average mean fluorescence intensity of CXCR2 expression 
on myeloid-derived suppressor cells (MDSCs) (CD11b+Ly6G+Ly6C+), 
macrophages (CD11b+F480+) and dendritic cells (CD11c+) isolated from the 
pancreas and spleens of tumor-bearing wild type and Cxcr2-/- mice. Each dot on 
the graph represents data point from an individual animal. Error bars represent 
standard deviation. B) Representative histograms demonstrating mean 
fluorescence intensity for MDSCs, macrophages and dendritic cells in tumors 
versus spleens chart.  
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Figure 6.3. Effect of host Cxcr2 deletion on the frequencies of myeloid cells 
in the pancreas and spleens of tumor-bearing mice.  
Effect of Cxcr2 deletion on the percentages of MDSCs, macrophages and 
dendritic cells in A) pancreas and B) spleens of wild type and Cxcr2-/- mice. Each 
dot on the graph represents data point from an individual animal. Error bars 
represent standard deviation.  
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Figure 6.4. Effect of host Cxcr2 deletion on the frequencies of myeloid cells 
in the pancreas and spleens of tumor-bearing mice. 
Representative photomicrographs demonstrating immunohistochemical (IHC) 
staining its quantitation for A) Ly6 in the tumors and B) F4/80 in tumors of wild 
type and Cxcr2-/- tumor-bearing mice. Each dot on the graph represents data 
point from an individual animal. Error bars represent standard deviation. IHC for 
Ly6 in C) cytospins prepared from splenocytes and D) spleens of wild type and 
Cxcr2-/- tumor-bearing mice.  
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Figure 6.5. Effect of host Cxcr2 deletion on the frequencies of T cell subset 
populations in the pancreas and spleens of tumor-bearing mice. 
Percentages of T helper cells (CD3+CD4+CD25-%CD3+), cytotoxic T cells 
(CD3+CD4-CD8+%CD3+) and T regulatory cells (Tregs) (CD3+CD4+CD25-
%CD3+) in A) pancreas and B) spleens of wild type and Cxcr2-/- mice. Each dot 
on the graph represents data point from an individual animal. Error bars 
represent standard deviation.  
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Figure 6.6. Effect of host Cxcr2 deletion on the ratio of cytotoxic T cell to 
myeloid-derived suppressor cell populations in the pancreas and spleens 
of tumor-bearing mice.  
Comparison of the ratios of myeloid-derived suppressor cells (MDSCs) and 
cytotoxic T cells in the A) pancreas or B) spleens of tumor-bearing wild type 
versus Cxcr2-/- mice groups.  
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Figure 6.7. Expression profile of cytokines in tumor-associated 
lymphocytes. 
Real time PCR data representing fold change in the levels of mRNA expression 
of  A) Ccl2, Ccl3 and Ccl5  B) IL-12, IL-10, IFNγ and TNFα in the lymphocytes 
isolated from the tumors (pancreas) of Cxcr2-/- versus the wild type mice groups. 
Error bars represent standard deviation. 
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Evaluation of CXCR2 antagonist as a therapeutic agent in preclinical 
models of pancreatic cancer 
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Abstract: 
Pancreatic cancer (PC) is known to have a poor prognosis. There is an 
urgent need for novel therapies for PC. We and others have shown the aberrant 
expression of CXCR2 and its ligands in PC. CXCR2 antagonists are currently in 
clinical trials for chronic obstructive pulmonary diseases. Therefore, targeting 
CXCR2 appears to be an attractive strategy. Our objective for this section of the 
study was to evaluate the therapeutic utility of CXCR2 antagonist in the 
preclinical models of PC. We investigated the effect of intraperitoneal 
administration of the CXCR2 antagonist (SCH-479833) in orthotopically 
implanted (syngeneic or xenogeneic) PC murine models. Our results 
demonstrate that systemic administration of CXCR2 antagonist had both tumor-
promoting and -inhibiting effect on PC. CXCR2 antagonist inhibited the 
proliferation of tumor cells. Furthermore, mirroring our results from host Cxcr2-/- 
study we observed increased accumulation of Ly6-positive cells in the spleens of 
CXCR2 antagonist-treated mice. To the best of our knowledge, the current study 
is the first effort to evaluate the impact of pharmacological inhibition of CXCR2 in 
preclinical models of PC. 
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Introduction: 
PC is in dire need of novel therapies. Results from the previous chapters 
provide evidence for the aberrant expression of CXCR2 and its ligands in PC. 
Analysis of human specimens demonstrated upregulation of CXCR2 and its 
ligands in PC tumor cells as well as the surrounding stroma. Furthermore, we 
identified an important role of this signaling axis in regulating KRAS(G12D)- 
induced autocrine growth of PC cells. Taken together, these findings suggest that 
CXCR2 can be a promising therapeutic target for PC. 
 Previous reports from our laboratory and others have demonstrated the 
utility of CXCR2 antagonists as anti-cancer agents in various cancer types. 
Treatment with CXCR2 antagonists inhibited the in vitro cell proliferation and 
chemotaxis of melanoma cells (Singh et al., 2009). Furthermore, administration 
of CXCR2 antagonists to nude mice having subcutaneous melanoma implants 
inhibited tumor growth and angiogenesis (Singh et al., 2007). In another report, 
we have shown the effectivity of CXCR2 antagonists as anti-metastatic 
therapeutics preclinically in human colon cancer (Varney et al., 2011).  Besides 
reports from our laboratory, a recent study reported that CXCR2 antagonist 
(SCH-527123) further sensitized colorectal cancer cells to oxaliplatin treatment 
(Ning et al., 2012a). In the previous sections of this dissertation, we have 
evaluated the therapeutic efficacy of CXCR2 antagonists in the context of 
KRAS(G12D) mutation in vitro on PC cells. Treatment of PC cells with CXCR2 
antagonists (SCH-527123 and SCH-479833) inhibited the in vitro growth and 
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migration of KRAS(G12D) mutation-bearing PC cell lines. However, our in vivo PC 
model with Cxcr2-/- host demonstrated no effect on tumor cell proliferation but 
had enhanced liver metastasis. Taken together, results from previous chapters 
suggested that CXCR2 inhibition in vivo in PC may have both tumor inhibitory 
and promoting effects. Therefore, based on our findings from preceding sections 
we were prompted to evaluate the impact of inhibiting CXCR2 pharmacologically 
in a preclinical murine model of PC. 
Results: 
Administration of CXCR2 antagonist to immunocompetent syngeneic 
pancreatic cancer murine model reduces tumor cell proliferation. 
In order to evaluate the effect of CXCR2 antagonist in a preclinical model 
of PC, we used a syngeneic orthotopically implanted murine PC model. KRAS-
PDAC-GFP cells (10 x 104) were injected into the pancreas of C57BL6 WT 
female mice by performing surgeries (Fig. 7.1A). A week after the surgeries, 
mice were assigned randomly to receive either control solvent HPβCD (100 µl) (n 
= 4) or the CXCR2 antagonist (SCH479833; 100 mg/kg body weight) once a day 
for seven days a week (Fig. 7.1A). Treatment with CXCR2 antagonist led to a 
minor increase in the tumor weight (Fig. 7.1B). This observation was consistent 
with our previous results in the host Cxcr2 deletion model. We observed no 
change in the histopathology of the tumors from the two treatment groups (Fig. 
7.1D). The frequency and weight of peritoneal metastasis were decreased in the 
CXCR2 antagonist-treated group. Tumor growth was assessed by performing 
IHC for Ki-67. We observed that treatment of PC-bearing mice with CXCR2 
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antagonists resulted in decreased tumor cell proliferation (Fig. 7.2A and B). 
Therefore, we conclude that systemic administration of CXCR2 antagonists 
slows the growth of tumor cells in orthotopically implanted model but did not 
reduce the tumor weight. 
Tumors from CXCR2 antagonist treated mice show reduced angiogenesis. 
 CXCR2 signaling axis has been widely implicated as a regulator of 
angiogenesis in PC. However, the impact of therapeutic inhibition of CXCR2 
signaling on angiogenesis has not yet been evaluated in preclinical murine PC 
model. We observed significant inhibition of angiogenesis in tumors of mice 
treated with CXCR2 antagonist compared with the control HPβCD-treated group 
(Fig. 7.3A). 
We next investigated the ability of CXCR2 antagonist treatment to impact 
fibrosis in murine PC. We performed Masson’s trichrome staining in these 
tumors. Consistent with our results in the host Cxcr2-/- model, we observed 
increased fibrosis in the tumors derived from mice treated with the CXCR2 
antagonist (Fig. 7.3B).  
Treatment with CXCR2 antagonist induces splenic accumulation of Ly6+ 
cells. 
 In the previous section, we observed enhanced accumulation of Ly6+ cells 
in the spleens of tumor-bearing Cxcr2-/- hosts. We, therefore, evaluated the 
impact of CXCR2 antagonist treatment on the frequency of Ly6+ cells in the 
spleens. We observed no change in the weight and histological architecture of 
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spleens derived from CXCR2 antagonist treated mice (Fig. 7.4A and B). 
However, we found an enhanced accumulation of Ly6+ populations in the 
follicular zone of the spleens of tumor-bearing mice treated with CXCR2 
antagonist compared with the control HPβCD group (Fig. 7.5A and B).  
Treatment with CXCR2 antagonist reduces tumor weight but enhances 
metastasis in the pancreatic cancer nude mouse model: 
 Based on our results thus far, we next attempted to evaluate the effect of 
treating immunodeficient mice bearing human PC cells with CXCR2 antagonist. 
For this purpose, we used two different human PC cell lines, CD18/HPAF and 
E6-E6-st-KRAS. The first model employed by us was generated by injecting 
CD18/HPAF cells in the pancreas of nude mice by performing surgeries. As 
shown in the figure 7.6 A, on day 7 of the surgeries mice were randomly divided 
into two groups. The control group (n = 4) received IP injections of 100 µl HPβCD 
for five continuous days a week.  The treatment group received CXCR2 
antagonist (SCH-479833; 100 mg/kg body weight) diluted in 100 µl HPβCD. Mice 
were sacrificed when they developed palpable tumors (day 28). 
 Treatment with CXCR2 antagonists decreased the weight of primary 
tumors (Fig 7.6B). There was no difference in the histopathology of the tumors 
derived from the two different groups (Fig 7.6C). Both HPβCD and CXCR2 
antagonist-treated groups developed metastasis (Fig 7.6D and E). Similarly, we 
developed another xenograft model by injecting E6-E7-st-KRAS cells in nude 
mice (Fig 7.7A). Treatment with CXCR2 antagonist decreased the weight of 
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primary tumors (Fig 7.7B). There was no difference in the histopathology of the 
tumors derived from the two different groups (Fig 7.7C). 
Discussion: 
 In this section of the study, we conclude that treatment of PC-bearing mice 
with CXCR2 antagonists has both anti- and pro-tumorigenic effects on the 
development of PC. Our findings in favor of this notion are as follows: tumors of 
mice treated with CXCR2 antagonist demonstrates i) inhibited tumor cell 
proliferation, ii) decreased angiogenesis, iii) enhanced fibrosis and iv) increased 
splenic accumulation of Ly6+ cells.  
We have previously (Chapter 4) demonstrated a growth inhibitory effect of 
CXCR2 antagonists on KRAS(G12D)- bearing PC cells in vitro. In this study, we 
found that IP administration of CXCR2 antagonist to immunocompetent mice 
bearing syngeneic PC cells inhibited tumor cell proliferation but did not affect the 
tumor size. An explanation of this discrepancy was provided by enhanced fibrosis 
in the SCH-479833 treated group. It is important to note that tumors in PC are 
composed of a heterogeneous population of cells including fibroblasts, immune 
and endothelial cells (Feig et al., 2012). The difference in responses of other 
cancers like colon (Singh et al., 2009) and melanoma (Varney et al., 2011) to 
CXCR2 antagonists versus PC could be due to the organ-specific 
microenvironment and host-induced responses.  
 In the previous sections, we demonstrated that Cxcr2 depletion in the host 
caused EMH and splenic expansion of MDSC population. Mirroring these 
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findings we have observed an increased population of Ly6+ cells in the spleens of 
CXCR2 antagonist-treated mice. Therefore, we conclude that systemic inhibition 
of CXCR2 by pharmacological as well as genetic approaches causes 
immunosuppression in the host. 
 CXCR2 is expressed by various cell types in the body. Furthermore, as 
CXCR2 has multiple ligands, it can affect different cell types and distinct ways. 
Therefore, the systemic administration of CXCR2 antagonists in PC needs to be 
carefully weighed.  
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Figure 7.1. Administration of CXCR2 antagonist to immunocompetent, 
syngeneic pancreatic cancer mouse model. 
 A) Experimental design for treatment of orthotopic pancreatic cancer mouse 
model with HPβCD (control) or SCH-479833 (CXCR2 antagonist). B) Weight 
(gms) of KRAS-PDAC-GFP tumors derived from mice treated with HPβCD or 
SCH-479833. C) Weight of peritoneal metastasis in the two treatment groups. D) 
Representative photomicrographs of H&E staining demonstrating the 
histopathology of tumors resected from the HPβCD- and SCH-479833-treated 
groups. Each dot on the graph represents data point from an individual animal. 
Error bars represent standard deviation.  
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Figure 7.2. Systemic administration of CXCR2 antagonist inhibits tumor cell 
proliferation. 
A) Representative photomicrographs demonstrating immunohistochemistry for 
Ki-67 in the tumor of HPβCD and SCH-479833 (CXCR2 antagonist) treated mice 
groups (n = 4). B) Comparison of the proliferation index of tumors from the two 
groups. Each dot on the graph represents data point from an individual animal. 
Error bars represent standard deviation. Statistical significance determined by 
Student’s t-test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, NS p > 0.05). 
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Figure 7.3. Decreased angiogenesis and enhanced fibrosis in CXCR2    
antagonist treated mice. 
A) Representative CD31 immunohistochemistry photographs and evaluation of 
microvessel density B) Masson’s trichrome staining on tumors derived from 
HPβCD and SCH-479833 (CXCR2 antagonist) treated mice groups (n = 4). Each 
dot on the graph represents data point from an individual animal. Error bars 
represent standard deviation. Statistical significance determined by Student’s t-
test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, NS p > 0.05). 
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Figure 7.4.  No effect on the weight and histological architecture of spleens 
in HPβCD and CXCR2 antagonist treated mice. 
A) Weight (gms) and B) histological architecture of the spleens isolated from 
mice treated with HPβCD (n = 4) or CXCR2 antagonist (SCH-479833) (n = 
5). Each dot on the graph represents data point from an individual animal. 
Error bars represent standard deviation.  
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Figure 7.5.  Treatment with CXCR2 antagonist induces splenic 
accumulation of Ly6+ cells. 
Images showing the immunohistochemistry for Ly6 in spleens of HPβCD- and 
CXCR2 antagonist (SCH-479833)-treated mice. 
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Figure 7.6. Administration of CXCR2 antagonist to immunocompromised 
nude mouse model bearing CD18/HPAF xenograft tumors reduces tumor 
weight but enhances peritoneal metastasis. 
A) Experimental design for treatment of orthotopic pancreatic cancer mouse 
model with HPβCD (control) or CXCR2 antagonist (SCH-479833). B) Weight of 
CD18/HPAF tumors derived from mice treated with HPβCD or SCH-479833. C) 
Representative photomicrographs of H&E staining of tumors. D) Weight of 
peritoneal metastasis in the two treatment groups. E) Table summarizing the 
incidence of metastasis in mice treated with HPβCD or SCH-479833. Each dot 
on the graph represents data point from an individual animal. Error bars 
represent standard deviation.  
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Figure 7.7. Administration of CXCR2 antagonist to immunocompromised 
nude mouse model bearing E6-E7-st-KRAS xenograft tumors. 
A) Experimental design for treatment of orthotopic pancreatic cancer mouse 
model with HPβCD (control) or CXCR2 antagonist (SCH-479833)  B) Weight of 
E6-E7-st-KRAS tumors derived from mice treated with HPβCD or SCH-479833. 
C) Representative photomicrographs of H&E staining of tumors. Each dot on the 
graph represents data point from an individual animal. Error bars represent 
standard deviation.  
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CXCR2 a double-edged sword in pancreatic cancer: a perspective 
PC is a complex disease that arises in a multi-step manner and involves 
several players regulating its pathogenesis. The unbridled growth and spread of 
the cancer cells is backed up by not just the genetic alterations in the tumor cells 
but also by active support from the cancer-bearing host. Targeted therapies have 
emerged as the new face of cancer treatment. Unlike standard chemotherapies 
that inhibit tumor growth by killing rapidly dividing cells, targeted therapies exert 
their effect by interfering with the activity of an identified target. An ideal target 
has differentially higher expression in the cancer cells. However, these proteins 
can be expressed by many of the healthy cells of the host as well. In such a 
scenario, there is the possibility of off-target effects that can create substantial 
unwanted outcomes. This emphasizes the need to analyze the impact of 
inhibiting any potential molecular target in the context of cancer cell versus 
normal noncancerous cells. Several published reports and our preliminary data 
have suggested the potential of CXCR2 as a “molecular target” for PC therapies. 
The purpose of the research presented in this dissertation was to identify the 
role(s) of CXCR2, a G-protein coupled receptor, in malignant PC tumor cells as 
well as in host-tumor interactions. Based on the results generated in this study 
we conclude that CXCR2 serves as a double-edged sword during PC 
progression (Fig. 8.1). Our conclusion is based on several observations upon 
inhibition of CXCR2 either in the tumor cells or in the cancer-bearing host. The 
first section of this chapter is a summary of the major findings and conclusions of   
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this dissertation. In the later section I present the future directions for this project 
by discussing the uninvestigated questions and suggestions of experiments to 
answer them. 
Summary and conclusions. 
Where and when are CXCR2 and its ligands expressed in PC? 
i) In human PC tissues hCXCR2 and its ligands hCXCL1 and hCXCL3 
are expressed in the normal pancreas as well as in PC. In PC tissues 
their expression is located on both malignant ducts and stroma. Acinar 
cells in normal pancreas express CXCR2; however, ducts in the normal 
pancreas are negative for this signaling.  
ii) In mice, only PDAC tissues express mCXCR2 and its ligands mCXCL1 
and mCXCL5 while the normal pancreas remains negative. 
iii) Upregulation of the CXCR2 signaling axis is an early event during PC 
development and is directly linked with the KRAS(G12D) mutation in vitro 
and in vivo. 
What is the significance of CXCR2 signaling in tumor cell autonomous growth in 
the context of the KRAS(G12D) mutation? 
i) The CXCR2 signaling axis mediates KRAS(G12D)-induced autocrine 
growth in vitro and in vivo in PDAC cells.  
ii) CXCR2 antagonists specifically inhibit the growth of KRAS(G12D)-bearing 
cells versus control counterparts having WT KRAS. 
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iii) Inhibiting CXCR2 signaling in PDAC cells down-regulates the protein 
levels of KRAS and inhibits the activation of the ERK pathway. 
iv) A KRAS-CXCR2 feed-forward loop amplifies autocrine growth 
promoting signals in PDAC cells. 
What is the significance of CXCR2 in tumor-host interaction during the 
progression of PC? 
i) Depletion of host Cxcr2 did not affect the growth of PC cells but 
enhanced their apoptosis. Therefore, host CXCR2 mainly regulates the 
survival of tumor cells. 
ii) Overall, host Cxcr2 depletion did not shrink the primary tumor. 
iii) Enhanced fibrosis in the tumors of Cxcr2-/- hosts compensates for any 
tumor size reduction due to the decreased survival of tumor cells. 
Therefore, we did not observe any tumor shrinkage in Cxcr2-/- hosts. 
iv) Enhanced fibrosis in tumors of Cxcr2-depleted host was specific to 
pancreatic parenchyma. 
v) Host Cxcr2 deletion increases metastasis to livers. 
vi) Decreased angiogenesis in tumors derived from Cxcr2-/- hosts. 
vii) Splenomegaly was observed in tumor-bearing Cxcr2-/- hosts. 
viii) Enhanced splenic accumulation of immature polymorphonuclear cells in 
tumor-bearing Cxcr2-/- hosts suggests increased EMH of myeloid 
precursors in these mice. 
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What is the significance of CXCR2 signaling in altering the dynamics of local and 
systemic immune responses to PC? 
i) CXCR2 is important for the recruitment of myeloid populations to the 
tumor and CXCR2 positive myeloid cells including MDSCs, 
macrophages, and dendritic cells are present in orthotopically implanted 
tumors. 
ii) Knock-down of host Cxcr2 results in the inhibited recruitment of MDSCs 
from spleens to the tumors. 
iii) Decreased frequency of MDSCs inside the tumors is accompanied with 
reduction in the populations of Treg cells.  
iv) Knocking-down of host Cxcr2 has no effect on the recruitment of 
macrophages. 
v) Knock-down of host Cxcr2 leads to the expansion of MDSCs in spleens. 
vi) Treatment of syngeneic immunocompetent mouse model with CXCR2 
antagonist also led to the expansion of Ly6+ populations inside the 
spleens. 
vii) Overall, knock-down of Cxcr2 in the host generates an anti-tumor 
immune response inside the TME but causes systemic immune 
suppression in the host.  
 
Figure 8.1 provides a synopsis of conclusions of this dissertation. 
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Directions for future work on this project: 
i) What are the pathways downstream of KRAS(G12D)  that upregulate the 
expression of CXCR2? 
Previous studies have reported that KRAS-induced upregulation of CXCR2 
ligands is mediated by pathways like ERK or AKT. We here identify a direct 
connection between KRAS(G12D) mutation and expression of CXCR2. However, 
the pathways downstream of KRAS that induce the expression of CXCR2 
remain unidentified. Therefore, as a next step we can identify activation of the 
pathways downstream of KRAS that cause the upregulation of CXCR2. In order 
to accomplish this objective we will treat human and mouse PC cell lines having 
KRAS(G12D) mutation with inhibitors for various signaling pathways, for example: 
ERK inhibitor (PD98590), PI3K/Akt pathway inhibitor (Wortmannin).  
ii) What is the contribution of the individual ligands of CXCR2 in KRAS(G12D) 
-induced PC? 
Reports suggest that KRAS-induced expression of CXCR2 ligands can exert 
functionally different outcomes in different cell types. For instance, CXCL1 was 
shown to induce senescence in fibroblasts while CXCL8 was found to be 
angiogenic. For future research, the role of an individual ligand in regulating 
KRAS(G12D) -induced autocrine and paracrine tumor-promoting roles in PC should 
be studied. This can help in mitigating the side effects generated by systemic 
inhibition of CXCR2.  
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iii) What will be the effect of deleting Cxcr2 specifically in the ductal cells of 
a spontaneous PC mouse model? 
To study the autocrine roles of CXCR2 in KRAS(G12D)-induced PC, we have used 
orthotopic and subcutaneous nude mouse models inoculated with PC cells 
having Cxcr2 depletion. As a logical step, the effect of deleting Cxcr2 at different 
time points in the ductal cells of a spontaneous PC model like Pdx1-cre;LSL-
Kras(G12D) should be evaluated. Alternatively, ductal cells can be isolated from 
Pdx1-cre;LSL-Kras(G12D)-Cxcr2-/- mice and cultured in vitro. In vitro tumor-
associated phenotypes should be evaluated. Furthermore, these cells can be 
implanted in the pancreas of WT C57BL6 mice. C57BL6 mice having pancreatic 
implantation of KRAS-PDAC cells will serve as the control group.  
iv) To evaluate how CXCR2 deletion in the host alters the frequency of 
mast cell infiltrations in the tumors? 
In chapter 1 we discussed the roles of mast cells in the PC TME and also 
presented information regarding the importance of CXCR2 in mast cell biology. 
We have evaluated the role of CXCR2 in regulating the infiltration of MDSCs, 
macrophages and dendritic cell. Future studies should evaluate the significance 
of CXCR2 in altering the infiltration of mast cells in PC. 
 
v) What will be the effect of deleting Cxcr2 in the bone marrow on the 
growth of PC? 
We have employed a mouse model having Cxcr2 deletion to study the host 
immune responses in PC. To specifically address the effect of Cxcr2 depletion in 
189 
 
the myeloid cell compartment, bone marrow from Cxcr2-/- mice can be 
transplanted to a spontaneous PC mouse model like Pdx1-cre;LSL-Kras(G12D). 
Tumor growth should be evaluated. Once the mice are sacrificed the altered 
frequencies of immune cell populations in these tumors should be studied by flow 
cytometry and IHC. 
vi) What will be the effect of splenectomizing mice at the time of implanting 
tumor cells in the pancreas? 
Our results in this study have demonstrated a peripheral immune suppression 
in spleens of tumor-bearing Cxcr2-/- hosts. Therefore, it would be interesting to 
analyze the impact of splenectomizing the WT and Cxcr2-/- mice at the time of 
performing pancreatic surgeries to inoculate tumor cells.  
vii) Will the precise delivery of CXCR2 antagonists to a specific cell type 
improve the therapeutic outcome? 
By employing adjuvant or proper delivery systems for targeting CXCR2 
antagonists to specific cell types, the side effects generated by overall systemic 
delivery of CXCR2 signaling can be reduced. 
             PC is in an urgent need of new molecular targets for designing improved 
therapeutics. In this dissertation we evaluated the significance of CXCR2 in PC 
pathology. The results presented here clearly suggest a dual tumor-promoting as 
wells as tumor-inhibiting role of CXCR2 in PC. We hope that these results will 
serve as a beacon for guiding the future research in this area. However, to reach 
an unequivocal conclusion further research efforts in this direction are essential.   
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Figure 8.1. CXCR2 signaling a double-edged sword in pancreatic cancer. 
Schematic representation of the effects of CXCR2 inhibition in a preclinical 
mouse model of pancreatic cancer. Systemic inhibition of CXCR2 results in 
differential tumor-promoting or –inhibiting effects in tumors versus the host. A) 
Anti-tumor effects of CXCR2 deletion are inhibition of tumor cell proliferation and 
reduced infiltration of myeloid-derived suppressor cells (MDSCs) and regulatory 
T cells (Tregs). B) The significance of fibrosis and angiogenesis are areas of 
contention in pancreatic cancer. Therefore, pro-fibrotic and anti-angiogenic effect 
of CXCR2 inhibition is classified as a dual effect (having pro- and anti-tumor 
impact). C) CXCR2 inhibition in the host causes extramedullary hematopoiesis of 
myeloid precursors and expansion of MDSCs inside the spleens resulting in 
systemic immune suppression and enhanced metastasis to livers. 
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